

Third National Health and Nutrition Examination Survey  
(NHANES III), 1988-94

NHANES III PRESCRIPTION MEDICINES DATA FILE DOCUMENTATION

Series 11, No. 2A

April 1998

\*Special Note:

(Response to prescription medicine questions)

This file contains the responses to the prescription medicine questions for prescription medicine users ONLY; listed as one record per prescription medicine taken. In addition to the information listed in "Adultx" and "Youthk", this file also contains the prescription medicine product codes. Data for both youth and adults are combined in this file. This file can be linked to "Adultx" and "Youthk" through the SEQN number; however, the rest of the variables in this file, which also appear in "Adultx" or "Youthk", have been given new variable names. This file contains an overview discussion about the prescription medicine section of the questionnaire as well as specific notes on selected variables.

Table of Contents

Introduction . . . . .

Guidelines for Data Users. . . . .

Survey Description . . . . .

Sample Design and Analysis Guidelines. . . . .

Data Preparation and Processing Procedures . . . . .

General References . . . . .

NHANES III Prescription Medicines Data File

    General Information . . . . .

    Data File Index . . . . .

    Data File Item Descriptions, Codes, Counts, and Notes . . . . .

    Appendices . . . . .

    References . . . . .

## Introduction

The National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) collects, analyzes, and disseminates data on the health status of U.S. residents. The results of surveys, analyses, and studies are made known through a number of data release mechanisms including publications, mainframe computer data files, CD-ROMs (Search and Retrieval Software, Statistical Export and Tabulation System (SETS)), and the Internet.

The National Health and Nutrition Examination Survey (NHANES) is a periodic survey conducted by NCHS. The third National Health and Nutrition Examination Survey (NHANES III), conducted from 1988 through 1994, was the seventh in a series of these surveys based on a complex, multi-stage sample plan. It was designed to provide national estimates of the health and nutritional status of the United States' civilian, noninstitutionalized population aged two months and older.

The following table summarizes the NHANES III data which are currently available on CD-ROM, including this release.

Table 1. Available NHANES III CD-ROMs

CD-ROM Name	Release Date	Size in Megabytes	Data Files / Description
NHANES III, 1988-94, Series 11, No. 2A, ASCII Version (this release)	April 1998	407	Dietary recall (replacement), electrocardiography, laboratory (additional analytes), and vitamins/medicines data files and documentation
NHANES III, 1988-94, Series 11, No. 1, Revised SETS Version 1.22a	October 1997	285	Adult and youth household questionnaire, examination, and laboratory data files and documentation, plan and operation, analytic and reporting guidelines, weighting and estimation methodology, field operations, non-response bias
NHANES III, 1988-94, Series 11, No. 1A, ASCII Version	July 1997	454	Adult and youth household questionnaire, dietary recall, examination, and laboratory data files and documentation
NHANES III, 1988-94, Series 11, No. 1, SETS Version 1.22a *	July 1997	285	Adult and youth household questionnaire, examination, and laboratory data files and documentation
NHANES III Reference Manuals and Reports October 1996	October 1996	152	Plan and operation, analytic and reporting guidelines, weighting and estimation methodology, field operations, non-response bias

\* Do not use this CD-ROM It had technical problems and has been superseded by the revised SETS version 1.22a, Series 11, No. 1, released in October 1997.

This release, Series 11, No. 2A, contains previously unreleased data and corrections. Corrections were made to the vitamin/minerals portion of the adult and youth questionnaire data files as well as the dietary recall portion of the examination data file. For the laboratory component, some previously release variables have been augmented with NHANES III Phase 2 data. In addition several new laboratory variables have been added.

The following table shows which public use files contain information from the interview and examination components.

Table 2. Location of the interview and examination components in the NHANES III public use data files

Data File

Topic	HA	HY	EXAM	LAB	DIET	VMS	ECG
Sample weights	X	X	X	X	.	.	X
Age/race/sex	X	X	X	X	.	.	X
Ethnic background	X	X	.	.	.	.	.
Household composition	X	X	.	.	.	.	.
Individual characteristics	X	X	.	.	.	.	.
Health insurance	X	X	.	.	.	.	.
Family background	X	X	.	.	.	.	.
Occupation of family head	X	X	.	.	.	.	.
Housing characteristics	X	X	.	.	.	.	.
Family characteristics	X	X	.	.	.	.	.
Orientation	X	X	.	.	.	.	.
Health services	X	X	.	.	.	.	.
Selected health conditions	X	X	X	.	.	.	.
Diabetes questions	X	.	.	.	.	.	.
High blood pressure and cholesterol questions	X	.	.	.	.	.	.
Cardiovascular disease questions	X	.	.	.	.	.	.
Musculoskeletal conditions	X	.	.	.	.	.	.
Physical functioning questions	X	.	.	.	.	.	.
Gallbladder disease questions	X	.	.	.	.	.	.

Table 2. (continued) Location of the interview and examination components in the NHANES III public use data files

	Data File							
Topic	HA	HY	EXAM	LAB	DIET	VMS	ECG	
Kidney conditions	X	.	.	.	.	.	.	.
Respiratory and allergy questions	X	X	.	.	.	.	.	.
Diet questions	X	.	.	.	.	.	.	.
Food frequency	X	.	X	.	.	.	.	.
Vision questions	X	X	.	.	.	.	.	.
Hearing questions	X	X	.	.	.	.	.	.
Dental care and status	X	X	.	.	.	.	.	.
Tobacco	X	.	X	.	.	.	.	.
Occupation	X	.	.	.	.	.	.	.
Language usage	X	X	.	.	.	.	.	.
Exercise	X	.	.	.	.	.	.	.
Social support/residence	X	.	.	.	.	.	.	.
Vitamin/mineral/medicine usage	X	X	X	.	.	.	.	.
Blood pressure measurement	X	.	X	.	.	.	.	.
Birth	.	X	X	.	.	.	.	.
Infant feeding practices/diet	.	X	.	.	.	.	.	.
Motor and social development	.	X	.	.	.	.	.	.
Functional impairment	X	X	.	.	.	.	.	.
School attendance	.	X	.	.	.	.	.	.
Cognitive function	.	X	X	.	.	.	.	.

Table 2. (continued) Location of the interview and examination components in the NHANES III public use data files

Data File

Topic	HA	HY	EXAM	LAB	DIET	VMS	ECG
Alcohol and drug use	.	.	X	.	.	.	.
Reproductive health	.	.	X	.	.	.	.
Diagnostic interview schedule	.	.	X	.	.	.	.
Activity	.	.	X	.	.	.	.
Physician's examination	.	.	X	.	.	.	.
Height and weight	.	.	X	.	.	.	.
Body measurements	.	.	X	.	.	.	.
Dental examination	.	.	X	.	.	.	.
Allergy skin test	.	.	X	.	.	.	.
Audiometry	.	.	X	.	.	.	.
Tympanometry	.	.	X	.	.	.	.
WISC and WRAT	.	.	X	.	.	.	.
Spirometry	.	.	X	.	.	.	.
Bone densitometry	.	.	X	.	.	.	.
Gallbladder ultrasonography	.	.	X	.	.	.	.
Central nervous system function evaluation	.	.	X	.	.	.	.
Fundus photography	.	.	X	.	.	.	.
Physical function evaluation	.	.	X	.	.	.	.
Fasting questions	.	.	.	X	.	.	.

Table 2. (continued) Location of the interview and examination components in the NHANES III public use data files

	Data File							
Topic	HA	HY	EXAM	LAB	DIET	VMS	ECG	
Laboratory tests on blood and urine	.	.	.	X	.	.	.	.
Total nutrient intakes	.	.	X	.	.	.	.	.
Individual foods	.	.	.	.	X	.	.	.
Combination foods	.	.	.	.	X	.	.	.
Ingredients	.	.	.	.	X	.	.	.
Prescription Medicines	X	X	.	.	.	X	.	.
Vitamins and Minerals	X	X	.	.	.	X	.	.
Electrocardiography	.	.	.	.	.	.	X	.

#### Data File Definitions

- HA - Household Adult Data File
- HY - Household Youth Data File
- EXAM - Examination Data File
- LAB - Laboratory Data File and Second Laboratory Data File
- DIET - Dietary Recall Data Files
- VMS - Vitamin Mineral Supplement Data File
- ECG - Electrocardiography Data File

This document includes the documentation for the NHANES III Prescription Medicines Data File and also contains a general overview of the survey and the use of the data files. The general overview includes five sections. The first section, entitled "Guidelines for Data Users," contains important information about the use of the data files. The second section, "Survey Description," is a brief overview of the survey plan and operation. The third section, "Sample Design and Analysis Guidelines," describes some technical aspects of the sampling plan and discusses some analytic issues particularly related to the use of data from complex sample surveys. The "Data Preparation and Processing Procedures" section describes the editing conventions and the codes used to represent the data. The last and fifth section, "General References," includes a reference list for the survey overview sections of the document.

Public Use Data Files for the third National Health and Nutrition Examination Survey will also be available from the National Technical Information Service (NTIS). A list of NCHS public use data tapes available for purchase from NTIS may be obtained from the Data Dissemination Branch at NCHS. Information regarding a bibliography (on disk) of journal articles citing data from all the NHANES and the availability of NHANES III data in



CD-ROM/SETS software format can be obtained from the Data Dissemination Branch at:

Data Dissemination Branch  
National Center for Health Statistics  
Room 1018  
6525 Belcrest Road  
Hyattsville, Maryland 20782

Phone: (301)436-8500

URL:<http://www.cdc.gov/nchswww>

NTIS can be contacted at:

NTIS - Computer Products Office  
5285 Port Royal Road  
Springfield, Virginia 22161  
(703) 487-4807

Copies of all NHANES III questionnaires and data collection forms are included in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94 (NCHS, 1994; U.S. DHHS, 1996). This publication, along with detailed information on NHANES procedures, interviewing, data collection, quality control techniques, survey design, nonresponse, and sample weighting can be found on the NHANES III Reference Manuals and Reports CD-ROM (U.S. DHHS, 1996). Information on how to order this CD-ROM is also available from the Data Dissemination Branch at NCHS at the address and telephone number given above.

## GUIDELINES FOR DATA USERS

Please refer to the following important information before analyzing data.

### NHANES III Background Documents

- o The Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94, (NCHS, 1994; U.S. DHHS, 1996) provides an overview of the survey and includes copies of the survey forms.
- o The sample design, nonresponse, and analytic guidelines documents on the NHANES III Reference Manuals and Reports CD-ROM (U.S. DHHS, 1996) discuss the reasons that sample weights and the complex survey design should be taken into account when conducting any analysis.
- o Instruction manuals, laboratory procedures, and other NHANES III reference manuals on the NHANES III Reference Manuals and Reports CD-ROM (U.S. DHHS, 1996) are also available for further information on the details of the survey.

### Analytic Data Set Preparation

- o Most NHANES III survey design and demographic variables are found only on the Adult and Youth Household Data Files available on the first release. In preparing a data set for analysis, other data files must be merged with either or both of these files to obtain many important analytic variables.
- o All of the NHANES III public use data files are linked with the common survey participant identification number (SEQN). Merging information from multiple NHANES III data files using this variable ensures that the appropriate information for each survey participant is linked correctly.
- o NHANES III public use data files do not have the same number of records on each file. The Household Questionnaire Files (divided into two files, Adult and Youth) contain more records than the Examination Data File because not everyone who was interviewed completed the examination. The Laboratory Data File contains data only for persons aged one year and older. The Individual Foods Data File based on the dietary recall has multiple records for each person rather than the one record per sample person contained in the other data files.
- o For each data file, SAS program code with standard variable names and labels is provided as separate text files on the CD-ROM that contains the data files. This SAS program code can be used to create a SAS data set from the data file.
- o Modifications were made to items in the questionnaires, laboratory, and examination components over the course of the survey; as a result, data may not be available for certain variables for the full six years. In addition, variables may differ by phase since some changes were

implemented between phases. Users are encouraged to read the Notes sections of this document carefully for information about changes.

- o Extremely high and low values have been verified whenever possible, and numerous consistency checks have been performed. Nonetheless, users should examine the range and frequency of values before analyzing data.
- o Some data were not ready for release at the time of this publication due to continued processing of the data or analysis of laboratory specimens. A listing of those data are available in the general information section of each data file.
- o Confidential and administrative data are not being released to the public. Additionally, some variables have been recoded to help protect the confidentiality of the survey participants. For example, all age-related variables were recoded to 90+ years for persons who were 90 years of age and older.
- o Some variable names may differ from those used in the Phase 1 NHANES III Provisional Data Release and some variables included in the Phase 1 provisional release may not appear on these files.
- o Although the data files have been edited carefully, errors may be detected. Please notify NCHS staff (301-436-8500) of any errors in the data file or the documentation.

#### Analytic Considerations

- o NHANES III (1988-94) was designed so that the survey's first three years, 1988-91, its last three years, 1991-94, and the entire six years were national probability samples. Analysts are encouraged to use all six years of survey results.
- o Sample weights are available for analyzing NHANES III data. One of the following three sample weights will be appropriate for nearly all analyses: interviewed sample final weight (WTPFQX6), examined sample final weight (WTPFEX6), and mobile examination center (MEC)- and home-examined sample final weight (WTPFHX6). Choosing which of these sample weights to use in any analysis depends on the variables being used. A good rule of thumb is to use "the least common denominator" approach. In this approach, the user checks the variables of interest. The variable that was collected on the smallest number of persons is the "least common denominator," and the sample weight that applies to that variable is the appropriate one to use for that analysis. For more detailed information, see the Analytic and Reporting Guidelines for NHANES III (U.S. DHHS, 1996).

#### Referencing or Citing NHANES III Data

- o In publications, please acknowledge NCHS as the original data source. For instance, the reference for the NHANES III Laboratory Data File On this CD-ROM is:

U.S. Department of Health and Human Services (DHHS). National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III Second Laboratory Data File (CD-ROM, Series 11, No. 2A). Hyattsville, MD.: Centers for Disease Control and Prevention, 1998.

- o Please place the acronym "NHANES III" in the titles or abstracts of journal articles and other publications in order to facilitate the retrieval of such materials in bibliographic searches.

## SURVEY DESCRIPTION

The third National Health and Nutrition Examination Survey (NHANES III) was the seventh in a series of large health examination surveys conducted in the United States beginning in 1960. Three of these surveys, the National Health Examination Surveys (NHES), were conducted in the 1960's (NCHS, 1965; NCHS, 1967; NCHS, 1969). In 1970, an expanded nutrition component was added to provide data with which to assess nutritional status and dietary practices, and the name was changed to the National Health and Nutrition Examination Survey (Miller, 1973; Engel, 1978; McDowell, 1981). A special survey of Hispanic populations in the United States was conducted during 1982-1984 (NCHS, 1985).

The general structure of the NHANES III sample design was similar to that of the previous NHANES. All of the surveys used complex, multi-stage, stratified, clustered samples of civilian, noninstitutionalized populations. NHANES III was the first NHANES without an upper age limit; in fact, the age range for the survey was two months and older. A home examination option was employed for the first time in order to obtain examination data for very young children and for elderly persons who were unable to visit the mobile examination center (MEC). The home examination included only a subset of the components used in the full MEC examination since it would have been difficult to collect some types of data in a home setting. A detailed description of design specifications and copies of the data collection forms can be found in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994 (NCHS, 1994; U.S. DHHS, 1996).

NHANES III was conducted from October 1988 through October 1994 in two phases, each of which comprised a national probability sample. The first phase was conducted from October 18, 1988, through October 24, 1991, at 44 locations. The second phase was conducted from September 20, 1991, through October 15, 1994, at 45 different locations. In NHANES III, 39,695 persons were selected over the six years; of those, 33,994 (86%) were interviewed in their homes. All interviewed persons were invited to the MEC for a medical examination. Seventy-eight percent (30,818) of the selected persons were examined in the MEC, and an additional 493 persons were given a special, limited examination in their homes.

Data collection began with a household interview. Several questionnaires were administered in the household: Household Screener Questionnaire, Family Questionnaire, Household Adult Questionnaire, and Household Youth Questionnaire.

At the MEC, an examination was performed, and five automated questionnaires or interviews were administered: MEC Adult Questionnaire, MEC Youth Questionnaire, MEC Proxy Questionnaire, 24-Hour Dietary Recall, and Dietary Food Frequency (ages 12-16 years). The health examination component included a variety of tests and procedures. The examinee's age at the time of the interview and other factors determined which procedures were administered. Blood and urine specimens were obtained, and a number of tests and measurements were performed including body measurements, spirometry, fundus photography, x-rays, electrocardiography, allergy and glucose tolerance tests, and ultrasonography. Measurements were taken of bone density, hearing, and physical, cognitive, and central nervous system

functions. A physician performed a limited standardized medical examination and a dentist performed a standardized dental examination. While some of the blood and urine analyses were performed in the MEC laboratory, most analyses were conducted elsewhere by contract laboratories.

A home examination was conducted for those sample persons aged 2-11 months and aged 20 years or older who were unable to visit the mobile examination center. The home examination consisted of an abbreviated version of the tests and interviews performed in the MEC. Depending on age of the sample person, the components included body measurements, blood pressure, spirometry, venipuncture, physical function evaluation, and a questionnaire to inquire about infant feeding, selected health conditions, cognitive function, tobacco use, and reproductive history.

## SAMPLE DESIGN AND ANALYSIS GUIDELINES

### Sample Design

The general structure of the NHANES III sample design is the same as that of the previous NHANES. Each of these surveys used a stratified, multi-stage probability design. The major design parameters of the two previous NHANES and the special Hispanic HANES, as well as NHANES III, have been previously summarized (Miller, 1973; McDowell, 1981; NCHS, 1985; NCHS, 1994). The NHANES III sample was designed to be self-weighting within a primary sampling unit (PSU) for subdomains (age, sex, and race-ethnic groups). While the sample was fairly close to self-weighting nationally for each of these subdomain groups, it was not representative of the total population, which includes institutionalized, non-civilian persons that were outside the scope of the survey.

The NHANES III sample represented the total civilian, noninstitutionalized population, two months of age or over, in the 50 states and the District of Columbia of the United States. The first stage of the design consisted of selecting a sample of 81 PSU's that were mostly individual counties. In a few cases, adjacent counties were combined to keep PSU's above a minimum population size. The PSU's were stratified and selected with probability proportional to size (PPS). Thirteen large counties (strata) were chosen with certainty (probability of one). For operational reasons, these 13 certainty PSU's were divided into 21 survey locations. After the 13 certainty strata were designated, the remaining PSU's in the United States were grouped into 34 strata, and two PSU's were selected per stratum (68 survey locations). The selection was done with PPS and without replacement. The NHANES III sample therefore consists of 81 PSU's or 89 locations.

The 89 locations were randomly divided into two groups, one for each phase. The first group consisted of 44 and the other of 45 locations. One set of PSU's was allocated to the first three-year survey period (1988-91) and the other set to the second three-year period (1991-94). Therefore, unbiased estimates (from the point of view of sample selection) of health and nutrition characteristics can be independently produced for both Phase 1 and Phase 2 as well as for both phases combined.

For most of the sample, the second stage of the design consisted of area segments composed of city or suburban blocks, combinations of blocks, or other area segments in places where block statistics were not produced in the 1980 Census. In the first phase of NHANES III, the area segments were used only for a sample of persons who lived in housing units built before 1980. For units built in 1980 and later, the second stage consisted of sets of addresses selected from building permits issued in 1980 or later. These are referred to as "new construction segments." In the second phase, 1990 Census data and maps were used to define the area segments. Because the second phase followed within a few years of the 1990 Census, new construction did not account for a significant part of the sample, and the entire sample came from the area segments.

The third stage of sample selection consisted of households and certain types of group quarters, such as dormitories. All households and eligible

group quarters in the sample segments were listed, and a subsample was designated for screening to identify potential sample persons. The subsampling rates enabled production of a national, approximately equal-probability sample of households in most of the United States with higher rates for the geographic strata with high Mexican-American populations. Within each geographic stratum, there was a nearly equal-probability sample of households across all 89 stands.

Persons within the sample of households or group quarters were the fourth stage of sample selection. All eligible members within a household were listed, and a subsample of individuals was selected based on sex, age, and race or ethnicity. The definitions of the sex, age, race or ethnic classes, subsampling rates, and designation of potential sample persons within screened households were developed to provide approximately self-weighting samples for each subdomain within geographic strata and at the same time to maximize the average number of sample persons per sample household. Previous NHANES indicated that this increased the overall participation rate. Although the exact sample sizes were not known until data collection was completed, estimates were made. Below is a summary of the sample sizes for the full six-year NHANES III at each stage of selection:

Number of PSU's	81
Number of stands (survey locations)	89
Number of segments	2,144
Number of households screened	93,653
Number of households with sample persons	19,528
Number of designated sample persons	39,695
Number of interviewed sample persons	33,994
Number of MEC-examined sample persons	30,818
Number of home-examined sample persons	493

More detailed information on the sample design and weighting and estimation procedures for NHANES III can be found in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94 (NCHS, 1994; U.S. DHHS, 1996) and in the Analytic and Reporting Guidelines: Third National Health and Nutrition Examination Survey (NHANES III), 1988-94 (U.S. DHHS, 1996).

#### Analysis Guidelines

Because of the complex survey design used in NHANES III, traditional methods of statistical analysis based on the assumption of a simple random sample are not applicable. Detailed descriptions of this issue and possible analytic methods for analyzing NHANES data have been described earlier (NCHS, 1985; Yetley, 1987; Landis, 1982; Delgado, 1990). Recent analytic and reporting guidelines that should be used for most NHANES III analyses and publications are contained in Analytic and Reporting Guidelines (U.S. DHHS, 1996). These recommendations differ slightly from those used by analysts for previous NHANES surveys. These suggested guidelines provide a framework to users for producing estimates that conform to the analytic design of the survey. All users are strongly urged to review these analytic and reporting guidelines before beginning any analyses of NHANES III data.

It is important to remember that this set of statistical guidelines is not absolute. When conducting analyses, the analyst needs to use his/her



subject matter knowledge (including methodological issues) as well as information about the survey design. The more one deviates from the original analytic categories defined in the sample design, the more important it is to evaluate the results carefully and to interpret the findings cautiously.

In NHANES III, 89 survey locations were randomly divided into two sets or phases, the first consisting of 44 and the other of 45 locations. One set of PSU's was allocated to the first three-year survey period (1988-91) and the other set to the second three-year period (1991-94). Therefore, unbiased national estimates of health and nutrition characteristics can be independently produced for each phase as well as for both phases combined. Computation of national estimates from both phases combined (i.e., total NHANES III) is the preferred option; individual phase estimates may be highly variable. In addition, individual phase estimates are not statistically independent. It is also difficult to evaluate whether differences in individual phase estimates are real or due to methodological differences. That is, differences may be due to changes in sampling methods or data collection methodology over time. At this time, there is no valid statistical test for examining differences between Phase 1 and Phase 2. Therefore, although point estimates can be produced separately for each phase, no test is available to test whether those estimates are significantly different from each other.

NHANES III is based on a complex, multi-stage probability sample design. Several aspects of the NHANES design must be taken into account in data analysis, including the sample weights and the complex survey design. Appropriate sample weights are needed to estimate prevalence, means, medians, and other statistics. Sample weights are used to produce correct population estimates because each sample person does not have the same probability of selection. The sample weights incorporate the differential probabilities of selection and include adjustments for noncoverage and nonresponse. A detailed discussion of nonresponse adjustments and issues related to survey coverage have been published (U.S. DHHS, 1996). With the large oversampling of young children, older persons, black persons, and Mexican-Americans in NHANES III, it is essential that the sample weights be used in all analyses. Otherwise, a misinterpretation of results is highly likely. Other aspects of the design that must be taken into account in data analyses are the strata and PSU pairings from the sample design. These pairings should be used to estimate variances and test for statistical significance. For weighted analyses, analysts can use special computer software packages that use an appropriate method for estimating variances for complex samples such as SUDAAN (Shah, 1995) and WesVarPC (Westat, 1996).

Although initial exploratory analyses may be performed on unweighted data using standard statistical packages and assuming simple random sampling, final analyses should be done on weighted data using appropriate sample weights. A summary of the weighting methodology and the type of sample weights developed for NHANES III is included in Weighting and Estimation Methodology (U.S. DHHS, 1996).

The purpose of weighting the sample data is to permit analysts to produce estimates of statistics that would have been obtained if the entire sampling frame (the United States) had been surveyed. Sample weights can be considered as measures of the number of persons the particular sample

observation represents. Weighting takes into account several features of

the survey: the specific probabilities of selection for the individual domains that were oversampled as well as nonresponse and differences between the sample and the total U.S. population. Differences between the sample and

the population may arise due to sampling variability, differential undercoverage in the survey among demographic groups, and possibly other types of response errors, such as differential response rates or misclassification errors. Sample weighting in NHANES III was used to:

1. Compensate for differential probabilities of selection among subgroups (i.e., age-sex-race-ethnicity subdomains where persons living in different geographic strata were sampled at different rates);
2. Reduce biases arising from the fact that nonrespondents may be different from those who participate;
3. Bring sample data up to the dimensions of the target population totals;
4. Compensate, to the extent possible, for inadequacies in the sampling frame (resulting from omissions of some housing units in the listing of area segments, omissions of persons with no fixed address, etc.); and
5. To reduce variances in the estimation procedure by using auxiliary information that is known with a high degree of accuracy.

In NHANES III, the sample weighting was carried out in three stages. The first stage involved the computation of weights to compensate for unequal probabilities of selection (objective 1, above). The second stage adjusted for nonresponse (objective 2). The third stage used poststratification of the sample weights to Census Bureau estimates of the U.S. population to accomplish the third, fourth, and fifth objectives simultaneously. In NHANES III, several types of sample weights (see the sample weights table that follows) were computed for the interviewed and examined sample and are included in the NHANES III data file. Also, sample weights were computed separately for Phase 1 (1988-91), Phase 2 (1991-94), and total NHANES III (1988-94) to facilitate analysis of items collected only in Phase 1, only in Phase 2, and over six years of the survey. Three sets of pseudo strata and PSU pairings are provided to use with SUDAAN in variance estimation. Since NHANES III is based on a complex, multi-stage sample design, appropriate sample weights should be used in analyses to produce national estimates of prevalence and associated variances while accounting for unequal probability of selection of sample persons. For example, the final interview weight, WTPFQX6, should be used for analysis of the items or questions from the family or household questionnaires, and the final MEC examination weight, WTPFEX6, should be used for analysis of the questionnaires and measurements administered in the MEC. Furthermore, for a combined analysis of measurements from the MEC examinations and associated medical history questions from the household interview, the final MEC examination weight, WTPFEX6, should be used. We recommend using SUDAAN (Shah, 1995) to estimate statistics of interest and the associated variance. However, one can also use other published methods for variance estimation. Application of SUDAAN and alternative methods, such as the average design effect approach, balance repeated replication (BRR) methods, or jackknife methods for variance estimation, are discussed in Weighting and Estimation Methodology (U.S. DHHS, 1996).

## Appropriate Uses of the NHANES III Sample Weights

Final interview weight, WTPFQX6

Use only in conjunction with the sample interviewed at home and with items collected during the household interview.

Final examination (MEC only) weight, WTPFEX6

Use only in conjunction with the MEC-examined sample and with interview and examination items collected at the MEC.

Final MEC+home examination weight, WTPFHX6

Use only in conjunction with the MEC+home-examined sample and with items collected at both the MEC and home.

Final allergy weight, WTPFALG6

Use only in conjunction with the allergy subsample and with items collected as part of the allergy component of the exam.

Final CNS weight, WTPFCNS6

Use only in conjunction with the CNS subsample and with items collected as part of the CNS component of the exam.

Final morning examination (MEC only) subsample weight, WTPFSD6

Use only in conjunction with the MEC-examined persons assigned to the morning subsample and only with items collected in the MEC exam.

Final afternoon/evening examination (MEC only) subsample weight, WTPFMD6

Use only in conjunction with the MEC-examined persons assigned to the afternoon/evening subsample and only with items collected in the MEC exam.

Final morning examination (MEC+home) subsample weight, WTPFHSD6

Use only in conjunction with the MEC- and home-examined persons assigned to the morning subsample and with items collected during the MEC and home examinations.

Final afternoon/evening examination (MEC+home) weight, WTPFHMD6

Use only in conjunction with the MEC- and home-examined persons assigned to the afternoon/evening subsample and with items collected during the MEC and home examinations.

#### DATA PREPARATION AND PROCESSING PROCEDURES

Automated data collection procedures for the survey were introduced in NHANES III. In the mobile examination centers, data for the interview and examination components were recorded directly onto a computerized data collection form. With the exception of a few independently automated systems, the system was centrally integrated. This operation allowed for ongoing monitoring of much of the data. Before the introduction of the computer-assisted personal interview (CAPI), the household questionnaire data were reviewed manually by field editors and interviewers. CAPI (1992-1994 only) questionnaires featured built-in edits to prevent entering inconsistencies and out-of-range responses. The multi-level data collection and quality control systems are discussed in detail in the Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994 (NCHS, 1994; U.S. DHHS, 1996). All interview, laboratory, and examination data were sent to NCHS for final processing.

Guidelines were developed that provided standards for naming variables, filling missing values and coding conventional responses, handling missing records, and standardizing two-part quantity/unit questionnaire variables. NCHS staff, assisted by contract staff, developed data editing specifications that checked data sets for valid codes, ranges, and skip pattern consistencies and examined the consistency of values between interrelated variables. Comments, collected in both interviews and examination components, were reviewed and recoded when possible. Responses to "Other" and "Specify" were recoded either to existing code categories or to new categories. The documentation for each data set includes notes for those variables that have been recoded and standardized and for those variables that differ significantly from what appears in the original data collection instrument. While the data have undergone many quality control and editing procedures, there still may be values that appear extreme or illogical. Values that varied considerably from what was expected were examined by analysts who checked for comments or other responses that might help to clarify unusual values. Generally, values were retained unless they could not possibly be true, in which case they were changed to "Blank but applicable." Therefore, the user must review each data set for extreme or inconsistent values and determine the status of each value for analysis.

Several editing conventions were used in the creation of final analytic data sets:

1. Standardized variables were created to replace all two-part quantity/unit questions using standard conversion factors. Standardized variables have the same name as the variable of the two-part question with an "S" suffix. For instance, MAPF18S (Months received WIC benefits) in the MEC Adult Questionnaire was created from the two-part response option to question F18, "How long did you receive benefits from the WIC program?," using the conversion factor 12 months per year.

2. Recoded variables were created by combining responses from two or more like variables, or by collapsing responses to create a summary variable for the purpose of confidentiality. Recoded variables have the original variable name with an R suffix. For example, place of birth

variable (HFA6X) in the Family Questionnaire was collapsed to a three level response category (U.S., Mexico, Other) and renamed HFA6XR. Generally, only the recoded variable has been included in the data file.

3. Fill values, a series of one or more digits, were used to represent certain specific conditions or responses. Below is a list of the fill values that were employed. Some of the fill values pertain only to questionnaire data, although 8-fill and blank-fill values are found in all data sets. Other fill values, not included in this list, are used to represent component-specific conditions.

6-fills = Varies/varied. (Questionnaires only)

7-fills = Fewer than the smallest number that could be reported within the question structure (e.g., fewer than one cigarette per day). (Questionnaires only)

8-fills = Blank but applicable/cannot be determined. This means that a respondent was eligible to receive the question, test, or component but did not because of refusal, lack of time, lack of staff, loss of data, broken vial, language barrier, unreliability, or other similar reasons.

9-fills = Don't know. This fill was used only when a respondent did not know the response to a question and said, "I don't know." (Questionnaires only)

Blank fills = Inapplicable. If a respondent was not eligible for a questionnaire, test, or component because of age, gender, or specific reason, the variable was blank-filled. In the questionnaire, if a respondent was not asked a question because of a skip-pattern, variables corresponding to the question were blank-filled. For examination or laboratory components, if a person was excluded by a defined protocol (e.g., screening exclusion questions) and these criteria are included in the data set, then the corresponding variables were blank-filled for that person. For home examinees, variables for examination components and blood tests not performed as part of the home examination protocol were blank-filled.

4. For variables describing discrete data, codes of zero (0) were used to mean "none," "never," or the equivalent. Value labels for which "0" is used include: "has not had," "never regularly," "still taking," or "never stopped using." Unless otherwise labeled, for variables containing continuous data, "zero" means "zero."
5. Where there are logical skip patterns in the flow of the questionnaire or examination component, the skip was indicated by placing the variable label of the skip destination in parentheses as part of the value label of the response generating the skip. For example, in the Physical Function Evaluation, the variable PFPWC (in wheelchair) has a

value label, "2 No (PFPSCOOT)" that means that the next item for persons not in a wheelchair would be represented by the variable, PFPSCOOT.

## Variable Nomenclature

A unique name was assigned to every NHANES III variable using a standard convention. By following this naming convention, the origin of each variable is clear, and there is no chance of overlaying similar variables across multiple components. Variables range in length from three to eight characters. The first two variable characters represent the topic (e.g., analyte, questionnaire instrument, examination component) and are listed below alphabetically by topic. For questionnaires administered in the household, the remainder of the variable name following the first two characters indicates the question section and number. For example, data for the response to the Household Adult Questionnaire question B1 are contained in the variable HAB1. For most laboratory and examination variables, as well as some other variables, a "P" in the third position refers to "primary" and the remainder of the variable name is a brief description of the item. For instance, in the Laboratory Data File, information on the length of time the person fasted before the first blood draw is contained in the variable PHPFAST. The variable PHPFAST was derived as follows: characters 1-2 (PH) refer to "phlebotomy," character 3 (P) refers to "primary," characters 4-8 (FAST) refer to an abbreviation for "fasting."

CODE	TOPIC
AT	Alanine aminotransferase (from biochemistry profile)
AM	Albumin (from biochemistry profile)
AP	Alkaline phosphatase (from biochemistry profile)
AL	Allergy skin test
AC	Alpha carotene
AN	Anisocytosis
TM	Antimicrosomal antibodies
TA	Antithyroglobulin antibodies
AA	Apolipoprotein (AI)
AB	Apolipoprotein (B)
AS	Aspartate aminotransferase (from biochemistry profile)
LA	Atypical lymphocyte
AU	Audiometry
BA	Band
BO	Basophil
BS	Basophilic stippling
BC	Beta carotene
BX	Beta cryptoxanthin
BL	Blast
BU	Blood urea nitrogen (BUN) (from biochemistry profile)
BM	Body measurements
BD	Bone densitometry
C1	C-peptide (first venipuncture)
C2	C-peptide (second venipuncture)
CR	C-reactive protein
UD	Cadmium
CN	Central nervous system function evaluation
CL	Chloride (from biochemistry profile)
CO	Cotinine
CE	Creatinine (serum)(from biochemistry profile)
UR	Creatinine (urine)
DM	Demographic

DE	Dental examination
MQ	Diagnostic interview schedule
DR	Dietary recall (total nutrient intakes)
EO	Eosinophil
EP	Erythrocyte protoporphyrin
FR	Ferritin
FB	Fibrinogen
RB	Folate (RBC)
FO	Folate (serum)
FH	Follicle stimulating hormone (FSH)
FP	Fundus photography
GG	Gamma glutamyl transferase (GGT) (from biochemistry profile)
GU	Gallbladder ultrasonography
GB	Globulin (from biochemistry profile)
G1	Glucose (first venipuncture)
G2	Glucose (second venipuncture)
SG	Glucose (from biochemistry profile)
GH	Glycated hemoglobin
GR	Granulocyte
C3	HCO <sub>3</sub> (Bicarbonate)(from biochemistry profile)
HD	HDL cholesterol
HP	Helicobacter pylori antibody
HT	Hematocrit
HG	Hemoglobin
AH	Hepatitis A antibody (HAV)
HB	Hepatitis B core antibody (anti-HBc)
SS	Hepatitis B surface antibody (anti-HBs)
SA	Hepatitis B surface antigen (HBsAg)
HC	Hepatitis C antibody (HCV)
DH	Hepatitis D antibody (HDV)
H1	Herpes 1 antibody
H2	Herpes 2 antibody
HX	Home examination (general)
HO	Homocysteine
HF	Household family questionnaire
HA	Household adult questionnaire
HQ	Household questionnaire variables (composite)
HS	Household screener questionnaire
HY	Household youth questionnaire
HZ	Hypochromia
I1	Insulin (first venipuncture)
I2	Insulin (second venipuncture)
UI	Iodine (urine)
FE	Iron
SF	Iron (from biochemistry profile)
LD	Lactate dehydrogenase (from biochemistry profile)
L1	Latex antibody
LC	LDL cholesterol (calculated)
PB	Lead
LP	Lipoprotein (a)
LH	Luteinizing hormone
LU	Lutein/zeaxanthin
LY	Lycopene
LM	Lymphocyte
MR	Macrocyte
MC	Mean cell hemoglobin (MCH)
MH	Mean cell hemoglobin concentration (MCHC)



MV	Mean cell volume (MCV)
PV	Mean platelet volume
MA	MEC adult questionnaire
MX	MEC examination (general)
FF	Dietary food frequency (ages 12-16 years)
MP	MEC proxy questionnaire
MY	MEC youth questionnaire
ME	Metamyelocyte
MI	Microcyte
MO	Monocyte
MN	Mononuclear cell
ML	Myelocyte
IC	Normalized calcium (derived from ionized calcium)
OS	Osmolality (from biochemistry profile)
PH	Phlebotomy data collected in MEC (e.g., questions)
PS	Phosphorus (from biochemistry profile)
PF	Physical function evaluation
PE	Physician's examination
PL	Platelet
DW	Platelet distribution width
PK	Poikilocytosis
PO	Polychromatophilia
SK	Potassium (from biochemistry profile)
PR	Promyelocyte
RC	Red blood cell count (RBC)
RW	Red cell distribution width (RDW)
RE	Retinyl esters
RF	Rheumatoid factor antibody
RU	Rubella antibody
WT	Sample weights
SE	Selenium
SI	Sickle cell
NA	Sodium (from biochemistry profile)
SH	Spherocyte
SP	Spirometry
SD	Survey design
TT	Target cell
TE	Tetanus
TH	Thyroid Stimulating Hormone (TSH)
T4	Thyroxine
TB	Total bilirubin (from biochemistry profile)
CA	Total calcium
SC	Total calcium (from biochemistry profile)
TC	Total cholesterol
CH	Total cholesterol (from biochemistry profile)
TI	Total iron binding capacity (TIBC)
TP	Total protein (from biochemistry profile)
TX	Toxic granulation
TO	Toxoplasmosis antibody
PX	Transferrin saturation
TG	Triglycerides
TR	Triglycerides (from biochemistry profile)
TY	Tympanometry
UA	Uric acid (from biochemistry profile)
UB	Urinary albumin
VU	Vacuolated cells
VR	Varicella antibody

VA	Vitamin A
VB	Vitamin B12
VC	Vitamin C
VD	Vitamin D
VE	Vitamin E
WC	White blood cell count (WBC)
WW	WISC/WRAT cognitive test

## GENERAL REFERENCES

- Delgado JL, Johnson CL, Roy I, Trevino FM. Hispanic Health and Nutrition Examination Survey: methodological considerations. Amer J Pub Health 80(suppl.):6-10. 1990.
- Engel A, Murphy RS, Maurer K, Collins E. Plan and operation of the HANES I Augmentation Survey of Adults 25-74 Years, United States, 1974-75. National Center for Health Statistics. Vital Health Stat 1(14). 1978.
- Freeman DH, Freeman JL, Brock DB, Koch GG. Strategies in the multivariate analysis of data from complex surveys II: an application to the United States National Health Interview Survey. Int Stat Rev 40(3):317-30. 1976.
- Khare M, Mohadjer LK, Ezzati-Rice TM, Waksberg J. An evaluation of nonresponse bias in NHANES III (1988-91). 1994 Proceedings of the Survey Research Methods section of the American Statistical Association. 1994.
- Landis JR, Lepkowski JM, Eklund SA, Stehouwer SA. A statistical methodology for analyzing data from a complex survey, the first National Health and Nutrition Examination Survey. National Center for Health Statistics. Vital Health Stat 2(92). 1982.
- McDowell A, Engel A, Massey JT, Maurer K. Plan and operation of the second National Health and Nutrition Examination Survey, 1976-80. National Center for Health Statistics. Vital Health Stat 1(15). 1981.
- Miller HW. Plan and operation of the Health and Nutrition Examination Survey, United States, 1971-1973. National Center for Health Statistics. Vital Health Stat 1(10a) and (10b). 1973.
- National Center for Health Statistics. Plan and initial program of the Health Examination Survey. Vital Health Stat 1(4). 1965.
- National Center for Health Statistics. Plan and operation of a health examination survey of U.S. youths 12-17 years of age. Vital Health Stat 1(8). 1969.
- National Center for Health Statistics. Plan and operation of the Hispanic Health and Nutrition Examination Survey, 1982-84. Vital Health Stat 1(19). 1985.
- National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Vital Health Stat 1(32). 1994.
- National Center for Health Statistics. Plan, operation, and response results of a program of children's examinations. Vital Health Stat 1(5). 1967.
- Shah BV, Barnwell BG, Bieler GS. SUDAAN User's Manual: Software for Analysis of Correlated Data. Research Triangle Park, NC: Research Triangle Institute. Release 6.04. 1995.
- Skinner CJ. Aggregated analysis: standard errors and significance tests.

In: Skinner CJ, Holt D, Smith TMF, eds. Analysis of complex surveys. New York: John Wiley and Sons, Inc. 1989.

U.S. Department of Health and Human Services (DHHS). National Center for Health Statistics. NHANES III reference manuals and reports (CD-ROM). Hyattsville, MD: Centers for Disease Control and Prevention, 1996. Available from National Technical Information Service (NTIS), Springfield, VA. Acrobat .PDF format; includes access software: Adobe Systems, Inc. Acrobat Reader 2.1.

Westat, Inc. A User's Guide to WesVarPC. Rockville, MD. Westat, Inc. 1996.

Yetley E, Johnson C. Nutritional applications of the Health and Nutrition Examination Surveys (HANES). Annu Rev Nutr 7:441-63. 1987.

## Household Questionnaire: Prescription Medicines

### General Information

During the household interview respondents were asked a series of questions about prescription medicines used during in the past month. A proxy, usually a child's parent or guardian, provided this information for children 2 months to 16 years of age. If respondents or proxy respondents reported taking a prescription medicine, they were asked the number of prescription medicines they took. For each medication reported, the interviewer asked to see the medication container in order to record the name of the product. If the container was not available, the interviewer probed for this information. Respondents or proxies were also asked to describe the health problem for which they took the medicine, and how long they had been taking the medicine. Analysts should be aware, however, that there were respondents or proxies who reported taking prescription medicines, but did not answer some or all of the remaining questions about the prescription medicines. In other cases respondents or proxies reported a health problem and/or duration they took a medication, but did not know the name of the medication or NCHS staff could not identify the name. In both cases, the missing fields are coded as either "blank but applicable" (8-fill) or "don't know" (9-fill), whichever was applicable.

Some prescription medicines originally reported in the supplements, antacid, or non-prescription drug sections of the questionnaire were moved to the prescription medicine section of the questionnaire. Some prescribed vitamin and/or mineral supplements, originally reported in the prescription medicines section, could be considered both a drug or a supplement (e.g., calciferol, niacin, calcitriol, and potassium). These products were copied to the dietary supplements section.

In general, non-prescription medications that were reported in the prescription drug section of the household adult questionnaire were moved to the non-prescription medications section (the expanded non-prescription pain relief medications section to be described later), but those medications reported on the household youth questionnaire were deleted since a non-prescription medications section was not included on the youth questionnaire. However, for both the household youth and adult questionnaires if a particular medication reported in the prescription medication section of the questionnaire was available in both prescription and non-prescription strengths (e.g., ibuprofen), the staff assumed it was a prescription medication and left it in this section. On the adult questionnaire, aspirin was moved to the non-prescription medications sections unless the strength or brand name reported was only available by prescription (e.g., "Zorprin"). Also on the household adult questionnaire, prescription antacids were left in this section, but over-the-counter antacids were moved to the antacid section unless, at the time of the survey, the antacid was only available by prescription (e.g., "Zantac").

Each prescription medicine name reported in the survey was located in the Physicians' GenRx, and assigned the standard generic name and 4-digit generic code for that product. However, for five prescription medications a generic name or code did not exist. The NCHS staff created product codes for these medicines. See the notes associated with this variable in the data file layout for a detailed discussion of the prescription medication product code. A list of the standardized generic prescription medication names and their associated product codes can be found in Appendix 1.

In some cases it may appear as though respondents reported the same prescription medicine more than once. That is, the same generic prescription medicine name and product code may be listed more than once. There are a number of reasons for these duplications. Respondents may have reported different brand name medicines which had the same generic name (e.g., "Adalat" vs. "Procardia"), or the medicines may have been different forms (e.g., tablet vs. patch), strengths (e.g., 20 mg vs. 30 mg), or dosages (e.g., once a day vs. twice a day) of the same product. Based on the information collected when respondents reported different brand names of the same generic product it was difficult to determine if these were duplicate listings or the individuals had taken more than one product in the month. Also, since descriptive information on the form, strength, and dosage of prescription medicines was not collected it was difficult to determine if these were reasons for the duplications. Hence, most of the duplicates have been left in the file.

Up to three drug class codes (i.e., primary, secondary, and tertiary) were assigned to each prescription medication that a respondent reported. These 4-digit codes came from the National Drug Code Directory prepared by the Product Information Management Branch of the Food and Drug Administration. See Appendix 2 for a listing of the drug class codes and descriptions.

Drug class codes were assigned for each medication, primarily based on the medication's action or response and, secondarily, on the health problem for which the respondent reported taking the medication. For example, all cardiovascular drugs that were beta-adrenergic blocking agents were assigned the drug class code for "Beta blockers" (512). Additional drug class codes were assigned based on the reason the respondent reported for taking the medication, for example, "Antiarrhythmics" (502) or "Antihypertensives" (506). Another example is the drug "Diazepam". The primary drug class code for "Diazepam" is sedative or hypnotic (626). If the respondent reported any of the following reasons for taking the drug, the drug class fields were also coded with these reasons: anxiety (627), muscle spasms (1373), or convulsive disorder (1374). If the reason the respondent gave did not relate to any of the actions of the drug, then only the medication-specific class code was assigned.

There are instances where the prescription medication product code and standard generic name are coded as "blank but applicable" (8-fill), but there is a valid primary drug class code. In these cases, the medication name and/or health condition that the respondent reported provided sufficient information in order to assign a drug class code.

ICD-9-CM codes were used to classify the health problem respondents gave for taking the prescription medicine. In general, the health problems were coded to the fourth digit ICD-9-CM level of specificity, but in some cases the highest level of specificity was only three digits and in other cases the level of specificity was five digits. See the notes associated with this variable in the data file layout for a detailed discussion of the ICD-9-CM codes. See Appendix 3 for a listing of the ICD-9-CM codes and descriptions.

As described earlier there were respondents who reported taking a prescription medicine but did not give a reason why they took the medicine. In these instances the ICD-9 codes are coded as "blank but applicable" (8-fill) or "don't know" (9-fill). On the other hand, there were respondents who reported a health problem but did not report the medication they were taking or NCHS staff could not identify it. In these cases the prescription medication

product code, and sometimes the drug class codes, are coded as "blank but applicable" (8-fill) or "don't know" (9-fill), but there is an ICD-9 code listed.

For each prescription medicine reported, respondents were also asked how long they had been taking the medicine. See the notes associated with this variable in the data file layout for a detailed discussion of this variable. When medicines were moved from the dietary supplements section to the prescription medicine section some of the categories for duration of use did not correspond. A response of "less than one month" in the supplements section was changed to "blank but applicable" (8-fill) in prescription medicine section.





	1015	88	Blank but applicable	
14-17			Primary drug class code	See note
HQKX9D	25809		0100-2100	
	1638		8888 Blank but applicable	
	327		9999 Don't know	

NHANES III Prescription Medicines Data File

-----  
HOUSEHOLD QUESTIONNAIRE  
-----

-----  
PRESCRIPTION MEDICINES  
-----

Positions SAS name	Counts	Item description and code	Notes
18-21 HQKX9E	5065	Secondary drug class code 0121-1900	See note
	22382	8888 Blank but applicable	
	327	9999 Don't know	
22-25 HQKX9F	192	Tertiary drug class code 0348-1271	See note
	27255	8888 Blank but applicable	
	327	9999 Don't know	
26-31 HQKX11A	25803	ICD-9-CM code V01.1-999.3	See note
	1449	888888 Blank but applicable	
	522	999999 Don't know	
32-36 HQKX12S		For how long have you been taking or using (MEDICINE)? (days)	See note
	26008	00001-23360	
	1267	88888 Blank but applicable	
	499	99999 Don't know	

Notes:

HQKX1B: Have you taken or used any prescription medicines in the past month?

This variable was the lead-in question for a series of questions on prescription medicine use, and includes prescription medicines reported in this section as well as prescription medicines moved from the supplements, antacid, or non-prescription drug sections of the questionnaire.

HQKX2B: Number of prescription medicines reported

This variable represents the total number of different prescription medicines reported by the respondent. The count includes all prescription medicines including those moved from other sections to the prescription medicines section.

HQRXCODE: Prescription medication product code

Each prescription medicine name reported in the survey was located in the Physicians' GenRx, and assigned the standard generic name and 4-digit generic code for that product. The prescription medication product code NCHS staff used for this variable is the same as the 4-digit generic code listed for each drug in this book. There were no generic names or codes for five prescription medications. These were: Insulin (7000); Kaolin, Paregoric, Pectin (7500); Hydrocodone Bitartrate (7501); Tiaprofenic Acid (7502); Diphenoxylate Hydrochloride (7503). The number in parentheses is the product code number NCHS staff assigned to these drugs. The generic name and product code were coded as "blank but applicable" (8-fill) when the name reported did not refer to a specific product (e.g., "cold tablet", "estrogen", "hormones", "antibiotic", or "water pill"), or when the name could not be identified. The name and code were coded as "don't know" (9-fill) when the respondent did not know the name of the product. A list of the standardized generic prescription medication names and their associated product codes can be found in Appendix 1.

HQKX9D: Primary drug class code

This variable contains the first of 3 possible drug class codes assigned to the prescription medication that was reported. These 4-digit codes came from the National Drug Code Directory. Drug class codes were assigned for each medication, primarily based on the medication's action or response and, secondarily, on the health problem for which the respondent reported taking the medication. This variable most likely contains the medication response. See Appendix 2 for a listing of the drug class codes and descriptions.

HQKX9E: Secondary drug class code

This variable contains the second drug class code for each prescription medication that was reported. Drug class codes were assigned for each medication, primarily based on the medication's action or response and, secondarily, on the health problem for which the respondent reported taking the medication. If this variable contains a drug class code it may be either based on the medication's action or the health problem for which the respondent

reported taking the medication. See Appendix 2 for a listing of the drug class codes and descriptions.

HQKX9F: Tertiary drug class code

This variable contains the third drug class code for each prescription medication that was reported. Drug class codes were assigned for each medication, primarily based on the medication's action or response and, secondarily, on the health problem for which the respondent reported taking the medication. If this variable contains a drug class code it may be either based on the medication's action or the health problem for which the respondent reported taking the medication. See Appendix 2 for a listing of the drug class codes and descriptions.

HQKX11A: ICD-9-CM code

ICD-9-CM codes were used to classify the health problem respondents reported as the reason for taking the prescription medicine. In general, the health problems were coded to the fourth digit ICD-9-CM level of specificity. However, in some cases the highest level of specificity for the ICD-9-CM code was only three digits and in other cases the level of specificity was five digits. When no appropriate code was available in the Classification of Diseases and Injuries ICD-9-CM codes, health problems were coded using V Codes - Supplementary Classification of Factors Influencing Health Status and Contact with Health Services. Some examples of these health problems were birth control, hormone replacement, and treatment to prevent infections. See Appendix 3 for a listing of the ICD-9-CM codes and descriptions.

HQKX12S: For how long have you been taking this medicine? (days)

This variable was created from the two-part (number and unit) question K12/X12, and indicates how long the respondent reported taking each prescription medicine. All responses were recoded to days. The conversion factors used were 7 days/week, 30.4 days/month and 365 days/year.

Appendix 1

Standardized Generic Prescription Medication Names

Rx Code	Standard Generic Prescription Medication Name
0002	ACEBUTOLOL HYDROCHLORIDE
0020	ACETAMINOPHEN; BUTALBITAL
0021	ACETAMINOPHEN; BUTALBITAL; CAFFEINE
0022	ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
0046	ACETAMINOPHEN; CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0048	ACETAMINOPHEN; CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE
0050	ACETAMINOPHEN; CHLORZOXAZONE
0051	ACETAMINOPHEN; CODEINE PHOSPHATE
0064	ACETAMINOPHEN; DICHLORALPHENAZONE; ISOMETHEPTENE MUCATE
0070	ACETAMINOPHEN; HYDROCODONE BITARTRATE
0072	ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
0074	ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE
0081	ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE
0082	ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE
0084	ACETAMINOPHEN; SALICYLAMIDE
0086	ACETAZOLAMIDE
0087	ACETIC ACID
0088	ACETIC ACID; HYDROCORTISONE
0092	ACETOHEXAMIDE
0105	ACYCLOVIR
0115	ALBUTEROL
0116	ALCLOMETASONE DIPROPIONATE

0133	ALLOPURINOL
0140	ALPRAZOLAM
0154	ALUMINUM CHLORIDE HEXAHYDRATE
0174	AMANTADINE HYDROCHLORIDE
0176	AMCINONIDE
0179	AMILORIDE HYDROCHLORIDE
0180	AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
0207	AMINOPHYLLINE
0212	AMIODARONE HYDROCHLORIDE
0213	AMITRIPTYLINE HYDROCHLORIDE
0214	AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE
0215	AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
0230	AMOXAPINE
0231	AMOXICILLIN
0232	AMOXICILLIN; CLAVULANATE POTASSIUM
0239	AMPICILLIN/AMPICILLIN TRIHYDRATE
0244	AMYLASE; CELLULASE; LIPASE; PROTEASE
0254	ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE
0255	ANTHRALIN
0260	ANTIHEMOPHILIC FACTOR, HUMAN
0263	ANTIPYRINE; BENZOCAINE
0264	ANTIPYRINE; BENZOCAINE; PHENYLEPHRINE HYDROCHLORIDE
0276	APRACLONIDINE HYDROCHLORIDE
0299	ASPIRIN
0302	ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
0304	ASPIRIN; BUTALBITAL; CAFFEINE
0306	ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE
0310	ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

0311 ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE  
0314 ASPIRIN; CARISOPRODOL  
0315 ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE  
0317 ASPIRIN; CODEINE PHOSPHATE  
0320 ASPIRIN; MEPROBAMATE  
0321 ASPIRIN; METHOCARBAMOL  
0322 ASPIRIN; OXYCODONE HYDROCHLORIDE;  
OXYCODONE TEREPHTHALATE  
0332 ASTEMIZOLE  
0333 ATENOLOL  
0334 ATENOLOL; CHLORTHALIDONE  
0336 ATROPINE SULFATE  
0338 ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE  
0339 ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE  
0340 ATROPINE SULFATE; BENZOIC ACID; HYOSCYAMINE;  
METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE  
0347 AURANOFIN  
0349 AZATADINE MALEATE  
0350 AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE  
0351 AZATHIOPRINE  
0356 BACITRACIN  
0357 BACITRACIN ZINC; NEOMYCIN SULFATE;  
POLYMYXIN B SULFATE  
0358 BACITRACIN ZINC; POLYMYXIN B SULFATE  
0361 BACLOFEN  
0376 BECLOMETHASONE DIPROPIONATE  
0380 BELLADONNA; CAFFEINE; ERGOTAMINE; PENTOBARBITAL  
0382 BELLADONNA  
0383 BELLADONNA ALKALOIDS; PHENOBARBITAL  
0389 BELLADONNA; ENZYME(S); PHENOBARBITAL

0391 BELLADONNA; KAOLIN; PAREGORIC; PECTIN

0403 BENDROFLUMETHIAZIDE; NADOLOL

0417 BENZOCAINE

0446 BENZONATATE

0447 BENZOYL PEROXIDE

0448 BENZOYL PEROXIDE; ERYTHROMYCIN

0455 BENZTROPINE MESYLATE

0462 BETAMETHASONE

0465 BETAMETHASONE DIPROPIONATE

0466 BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

0468 BETAMETHASONE VALERATE

0469 BETAXOLOL HYDROCHLORIDE

0470 BETHANECHOL CHLORIDE

0476 BILE SALTS; PANCREATIN; PEP SIN

0505 BITOLTEROL MESYLATE

0527 BROMOCRIPTINE MESYLATE

0528 BROMODIPHENHYDRAMINE HYDROCHLORIDE;  
CODEINE PHOSPHATE

0529 BROMPHENIRAMINE MALEATE

0530 BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE;  
PHENYLPROPANOLAMINE HYDROCHLORIDE

0531 BROMPHENIRAMINE MALEATE;  
DEXTROMETHORPHAN HYDROBROMIDE;  
PSEUDOEPHEDRINE HYDROCHLORIDE

0532 BROMPHENIRAMINE MALEATE;  
PHENYLPROPANOLAMINE HYDROCHLORIDE

0533 BROMPHENIRAMINE MALEATE;  
PSEUDOEPHEDRINE HYDROCHLORIDE

0534 BROMPHENIRAMINE; DEXTROMETHORPHAN;  
PHENYLPROPANOLAMINE

0538 BROMPHENIRAMINE; PHENYLEPHRINE HYDROCHLORIDE;  
PHENYLTOLOXAMINE

0544 BUMETANIDE

0550 BUPROPION HYDROCHLORIDE

0551 BUSPIRONE HYDROCHLORIDE

0557 BUTABARBITAL SODIUM

0574 CAFFEINE; ERGOTAMINE TARTRATE

0585 CALCITONIN, SALMON

0586 CALCITRIOL

0607 CALCIUM IODIDE; CODEINE PHOSPHATE

0642 CAPTOPRIL

0643 CAPTOPRIL; HYDROCHLOROTHIAZIDE

0644 CARAMIPHEN; PHENYLPROPANOLAMINE

0645 CARBACHOL

0646 CARBAMAZEPINE

0652 CARBETAPENTANE TANNATE; CHLORPHENIRAMINE TANNATE;  
EPHEDRINE TANNATE; PHENYLEPHRINE HYDROCHLORIDE

0653 CARBIDOPA; LEVODOPA

0655 CARBINOXAMINE MALEATE;  
DEXTROMETHORPHAN HYDROBROMIDE;  
PSEUDOEPHEDRINE HYDROCHLORIDE

0656 CARBINOXAMINE MALEATE;  
PSEUDOEPHEDRINE HYDROCHLORIDE

0664 CARISOPRODOL

0666 CARTEOLOL HYDROCHLORIDE

0680 CEFACLOR

0681 CEFADROXIL

0684 CEFIXIME

0687 CEFOPERAZONE SODIUM

0694 CEFTRIAZONE SODIUM

0695 CEFUROXIME AXETIL

0698 CEPHALEXIN

0699 CEPHALEXIN HYDROCHLORIDE



0702 CEPHRADINE

0726 CHLORDIAZEPOXIDE HYDROCHLORIDE

0727 CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

0728 CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

0729 CHLORHEXIDINE GLUCONATE

0738 CHLOROQUINE PHOSPHATE

0739 CHLOROTHIAZIDE

0740 CHLOROTHIAZIDE; METHYLDOPA

0741 CHLOROTHIAZIDE; RESERPINE

0743 CHLOROXINE

0749 CHLORPHENIRAMINE MALEATE; HYDROCODONE;  
PHENYLEPHRINE HYDROCHLORIDE

0751 CHLORPHENIRAMINE MALEATE

0753 CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE;  
PSEUDOEPHEDRINE HYDROCHLORIDE

0754 CHLORPHENIRAMINE MALEATE; EPINEPHRINE

0755 CHLORPHENIRAMINE MALEATE; METHSCOPOLAMINE NITRATE;  
PHENYLEPHRINE HYDROCHLORIDE

0756 CHLORPHENIRAMINE MALEATE; PHENINDAMINE TARTRATE;  
PHENYLPROPANOLAMINE HYDROCHLORIDE

0757 CHLORPHENIRAMINE MALEATE;  
PHENYLEPHRINE HYDROCHLORIDE;  
PHENYLTOLOXAMINE CITRATE

0758 CHLORPHENIRAMINE MALEATE;  
PHENYLPROPANOLAMINE HYDROCHLORIDE

0759 CHLORPHENIRAMINE MALEATE;  
PSEUDOEPHEDRINE HYDROCHLORIDE

0760 CHLORPHENIRAMINE POLISTIREX;  
HYDROCODONE POLISTIREX

0761 CHLORPHENIRAMINE TANNATE; PHENYLEPHRINE TANNATE;  
PYRILAMINE TANNATE

0767 CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE;  
PHENYLEPHRINE HYDROCHLORIDE; POTASSIUM IODIDE

0775 CHLORPHENIRAMINE MALEATE; DEXTROMETHORPHAN;  
GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE

0776	BECLOMETHASONE DIPROPIONATE
0790	CHLORPHENIRAMINE MALEATE; HYDROCODONE; PSEUDOEPHEDRINE
0792	CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE; PHENYLTOLOXAMINE
0793	CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE; PYRILAMINE
0797	CHLORPROMAZINE HYDROCHLORIDE
0798	CHLORPROPAMIDE
0801	CHLORTHALIDONE
0802	CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE
0803	CHLORTHALIDONE; RESERPINE
0804	CHLORZOXAZONE
0808	CHOLESTYRAMINE
0811	CHOLINE MAGNESIUM TRISALICYLATE
0817	CICLOPIROX OLAMINE
0820	CIMETIDINE
0823	CIPROFLOXACIN HYDROCHLORIDE
0830	CITRIC ACID; SODIUM CITRATE
0835	CLEMASTINE FUMARATE
0836	CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
0838	CLINDAMYCIN HYDROCHLORIDE
0839	CLOBETASOL PROPIONATE
0842	CLOFIBRATE
0843	CLOMIPHENE CITRATE
0845	CLONAZEPAM
0846	CLONIDINE HYDROCHLORIDE
0847	CLORAZEPATE DIPOTASSIUM

0848	CLOTRIMAZOLE
0850	CLOXACILLIN SODIUM
0851	CLOZAPINE
0870	CODEINE PHOSPHATE
0873	CODEINE PHOSPHATE; GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE
0874	CODEINE PHOSPHATE; IODINATED GLYCEROL
0875	CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
0876	CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
0878	CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
0881	CODEINE PHOSPHATE; GUAIFENESIN
0883	CODEINE PHOSPHATE; GUAIFENESIN; PHENYLPROPANOLAMINE
0890	COLCHICINE
0891	COLCHICINE; PROBENECID
0892	COLESTIPOL HYDROCHLORIDE
0894	COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE
0907	CORTISONE ACETATE
0916	CROMOLYN SODIUM
0924	CYCLANDELATE
0926	CYCLOBENZAPRINE HYDROCHLORIDE
0930	CYCLOPHOSPHAMIDE
0932	CYCLOSPORINE
0934	CYPROHEPTADINE HYDROCHLORIDE
0940	DANAZOL
0944	DANTROLENE SODIUM
0947	DEFEROXAMINE MESYLATE
0951	DEHYDROCHOLIC ACID

0963	DESERPIDINE; METHYCLOTHIAZIDE
0964	DESIPRAMINE HYDROCHLORIDE
0966	DESMOPRESSIN ACETATE
0967	DESONIDE
0968	DESOXIMETASONE
0974	DEXAMETHASONE
0976	DEXAMETHASONE SODIUM PHOSPHATE
0978	DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE
0979	DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
0980	DEXAMETHASONE; TOBRAMYCIN
0982	DEXBROMPHENIRAMINE; PSEUDOEPHEDRINE
0983	DEXCHLORPHENIRAMINE MALEATE
0987	DEXTRAN
0992	DEXTROAMPHETAMINE SULFATE
0994	DEXTROMETHORPHAN HYDROBROMIDE; IODINATED GLYCEROL
0995	DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE
1000	DEXTROMETHORPHAN; GUAIFENESIN
1033	DIAZEPAM
1044	DICHLORPHENAMIDE
1045	DICLOFENAC SODIUM
1046	DICLOXACILLIN SODIUM
1048	DICYCLOMINE HYDROCHLORIDE
1050	DIENESTROL
1053	DIETHYLPROPION HYDROCHLORIDE
1054	DIETHYLSTILBESTROL
1055	DIETHYLSTILBESTROL DIPHOSPHATE
1057	DIFLORASONE DIACETATE
1058	DIFLUNISAL

1060	DIGITOXIN
1061	DIGOXIN
1063	DIHYDROERGOTAMINE MESYLATE
1065	DIHYDROTACHYSTEROL
1068	HYDROCORTISONE; IODOQUINOL
1069	DILTIAZEM HYDROCHLORIDE
1070	DIMENHYDRINATE
1079	DIPHENHYDRAMINE HYDROCHLORIDE
1088	DIPIVEFRIN HYDROCHLORIDE
1090	DIPYRIDAMOLE
1093	DISOPYRAMIDE PHOSPHATE
1096	DIVALPROEX SODIUM
1111	DOXEPIN HYDROCHLORIDE
1113	DOXYCYCLINE
1122	DYPHYLLINE
1124	DYPHYLLINE; GUAIFENESIN
1126	ECHOTHIOPHATE IODIDE
1127	ECONAZOLE NITRATE
1138	ENALAPRIL MALEATE
1139	ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
1141	ENCAINIDE HYDROCHLORIDE
1145	ENZYME(S); HYOSCYAMINE SULFATE; PHENYLTOLOXAMINE CITRATE
1149	EPHEDRINE
1151	EPHEDRINE HYDROCHLORIDE; PHENOBARBITAL; THEOPHYLLINE ANHYDROUS
1152	EPHEDRINE SULFATE; HYDROXYZINE HYDROCHLORIDE; THEOPHYLLINE
1160	EPHEDRINE HYDROCHLORIDE; POTASSIUM IODIDE; PHENOBARBITAL; THEOPHYLLINE

1166	EPINEPHRINE
1169	EPINEPHRYL BORATE
1172	EPINEPHRINE; PILOCARPINE
1173	EPOETIN ALFA
1174	ERGOCALCIFEROL
1175	ERGOLOID MESYLATES
1177	ERGOTAMINE TARTRATE
1178	ERYTHRITYL TETRANITRATE
1179	ERYTHROMYCIN
1180	ERYTHROMYCIN ESTOLATE
1181	ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL
1182	ERYTHROMYCIN ETHYLSUCCINATE
1184	ERYTHROMYCIN LACTOBIONATE
1185	ERYTHROMYCIN STEARATE
1188	ESTRADIOL
1191	ESTRADIOL VALERATE
1195	ESTRAMUSTINE PHOSPHATE SODIUM
1196	ESTROGENIC SUBSTANCES
1197	ESTROGENS, CONJUGATED
1200	ESTROGENS, ESTERIFIED
1201	ESTROGENS, ESTERIFIED; METHYLTESTOSTERONE
1204	ESTROPIPATE
1206	ETHAMBUTOL HYDROCHLORIDE
1208	ETHAVERINE HYDROCHLORIDE
1213	ETHCHLORVYNOL
1216	ETHINYL ESTRADIOL
1217	ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE
1219	ETHINYL ESTRADIOL; LEVONORGESTREL
1220	ETHINYL ESTRADIOL; NORETHINDRONE

1221	ETHINYL ESTRADIOL; NORETHINDRONE ACETATE; FERROUS FUMARATE
1222	ETHINYL ESTRADIOL; NORGESTREL
1226	ETHOSUXIMIDE
1234	ETIDRONATE DISODIUM
1237	ETRETINATE
1246	FAMOTIDINE
1253	FENOPROFEN CALCIUM
1297	FLAVOXATE HYDROCHLORIDE
1299	FLECAINIDE ACETATE
1301	FLUCONAZOLE
1303	FLUDROCORTISONE ACETATE
1305	FLUNISOLIDE
1306	FLUOCINOLONE ACETONIDE
1310	FLUOCINONIDE
1317	FLUOROMETHOLONE
1319	FLUOROURACIL
1320	FLUOXETINE HYDROCHLORIDE
1321	FLUOXYMESTERONE
1322	FLUPHENAZINE DECANOATE
1324	FLUPHENAZINE HYDROCHLORIDE
1325	FLURANDRENOLIDE
1327	FLURAZEPAM HYDROCHLORIDE
1328	FLURBIPROFEN
1330	FLUTAMIDE
1331	FOLIC ACID
1342	FUROSEMIDE
1351	GEMFIBROZIL
1352	GENTAMICIN SULFATE

1353 GENTAMICIN SULFATE; PREDNISOLONE ACETATE  
1357 GLIPIZIDE  
1366 GLUTETHIMIDE  
1368 GLYBURIDE  
1377 GLYCOPYRROLATE  
1379 GOLD SODIUM THIOMALATE  
1382 GOSERELIN ACETATE  
1385 GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE  
1388 GRISEOFULVIN, MICROCRYSTALLINE  
1389 GRISEOFULVIN, ULTRAMICROCRYSTALLINE  
1391 GUAIFENESIN  
1395 GUAIFENESIN; HYDROCODONE BITARTRATE  
1402 GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE  
1403 GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE;  
PHENYLPROPANOLAMINE HYDROCHLORIDE  
1404 GUAIFENESIN; PHENYLPROPANOLAMINE HYDROCHLORIDE  
1405 GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE  
1406 GUAIFENESIN; PSEUDOEPHEDRINE; THEOPHYLLINE  
1407 GUAIFENESIN; THEOPHYLLINE  
1408 GUANABENZ ACETATE  
1410 GUANETHIDINE MONOSULFATE  
1412 GUANFACINE HYDROCHLORIDE  
1418 HALOPERIDOL  
1419 HALOPERIDOL DECANOATE  
1427 HEPARIN LOCK FLUSH  
1436 HEXACHLOROPHENE  
1440 HISTAMINE PHOSPHATE  
1444 HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE  
1450 HYDRALAZINE HYDROCHLORIDE



1451           HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

1452           HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE;  
RESERPINE

1456           HYDROCHLOROTHIAZIDE

1457           HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

1458           HYDROCHLOROTHIAZIDE; LISINAPRIL

1459           HYDROCHLOROTHIAZIDE; METHYLDOPA

1460           HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

1461           HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

1462           HYDROCHLOROTHIAZIDE; RESERPINE

1463           HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

1464           HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

1465           HYDROCHLOROTHIAZIDE; TRIAMTERENE

1468           HYDROCODONE BITARTRATE;  
PHENYLEPHRINE HYDROCHLORIDE;  
PHENYLPROPANOLAMINE HYDROCHLORIDE; PYRILAMINE

1469           HYDROCODONE BITARTRATE;  
PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

1470           HYDROCODONE BITARTRATE;  
PHENYLPROPANOLAMINE HYDROCHLORIDE

1476           HYDROCORTISONE

1477           HYDROCORTISONE ACETATE

1480           HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

1482           HYDROCORTISONE BUTYRATE

1483           HYDROCORTISONE CYPIONATE

1485           HYDROCORTISONE SODIUM SUCCINATE

1486           HYDROCORTISONE VALERATE

1490           HYDROCORTISONE; NEOMYCIN SULFATE;  
POLYMYXIN B SULFATE

1496           HYDROFLUMETHIAZIDE

1497           HYDROFLUMETHIAZIDE; RESERPINE

1500	HYDROMORPHONE HYDROCHLORIDE
1506	HYDROXYCHLOROQUINE SULFATE
1512	HYDROXYUREA
1513	HYDROXYZINE HYDROCHLORIDE
1514	HYDROXYZINE PAMOATE
1516	HYOSCYAMINE SULFATE
1517	HYOSCYAMINE SULFATE; PHENOBARBITAL
1520	IBUPROFEN
1525	IMIPRAMINE HYDROCHLORIDE
1526	IMIPRAMINE PAMOATE
1529	INDAPAMIDE
1532	INDOMETHACIN
1546	INTERFERON ALFA-2B, RECOMBINANT
1555	IODINATED GLYCEROL
1556	IODINATED GLYCEROL; THEOPHYLLINE
1557	IODINE
1578	IPRATROPIUM BROMIDE
1581	ISOCARBOXAZID
1583	ISOETHARINE MESYLATE
1585	ISONIAZID
1587	ISONIAZID; RIFAMPIN
1590	ISOPROTERENOL HYDROCHLORIDE
1592	ISOSORBIDE
1593	ISOSORBIDE DINITRATE
1595	ISOTRETINOIN
1596	ISOXSUPRINE HYDROCHLORIDE
1605	KETOCONAZOLE
1606	KETOPROFEN
1607	KETOROLAC TROMETHAMINE

1612	LEVOTHYROXINE SODIUM
1613	LABETALOL HYDROCHLORIDE
1621	LACTULOSE
1630	LEUCOVORIN CALCIUM
1631	LEUPROLIDE ACETATE
1632	LEVAMISOLE HYDROCHLORIDE
1633	LEVOBUNOLOL HYDROCHLORIDE
1634	LEVOCARNITINE
1635	LEVODOPA
1638	LIDOCAINE
1639	LIDOCAINE HYDROCHLORIDE
1641	LINCOMYCIN HYDROCHLORIDE
1642	LINDANE
1645	LIOTHYRONINE SODIUM
1646	LIOTRIX (T4,T3)
1647	LISINOPRIL
1648	LITHIUM CARBONATE
1660	LOMUSTINE
1661	LOPERAMIDE HYDROCHLORIDE
1662	LORAZEPAM
1664	LOVASTATIN
1666	LOXAPINE SUCCINATE
1677	MAGALDRATE; SIMETHICONE
1695	MANGANESE
1705	MEBENDAZOLE
1708	MECLIZINE HYDROCHLORIDE
1710	MECLOFENAMATE SODIUM
1712	MEDROXYPROGESTERONE ACETATE

1713	MEDRYSONE
1714	MEFENAMIC ACID
1716	MEGESTROL ACETATE
1726	MEPENZOLATE BROMIDE
1727	MEPERIDINE HYDROCHLORIDE
1728	MEPERIDINE HYDROCHLORIDE ; PROMETHAZINE HYDROCHLORIDE
1731	MEPHOBARBITAL
1734	MEPROBAMATE
1737	MERCAPTOPYRINE
1742	MESALAMINE
1744	MESORIDAZINE BESYLATE
1747	METAPROTERENOL SULFATE
1749	METAXALONE
1753	METHADONE HYDROCHLORIDE
1759	METHAZOLAMIDE
1761	METHENAMINE HIPPURATE
1762	METHENAMINE MANDELATE
1765	METHIMAZOLE
1767	METHIONINE ; SODIUM PROPIONATE ; UREA
1768	METHOCARBAMOL
1770	METHOTREXATE SODIUM
1777	METHSUXIMIDE
1778	METHYCLOTHIAZIDE
1780	METHYCLOTHIAZIDE ; RESERPINE
1787	METHYLDOPA
1789	METHYLERGONOVINE MALEATE
1790	METHYLPHENIDATE HYDROCHLORIDE
1791	METHYLPREDNISOLONE

1795	METHYLTESTOSTERONE
1798	METOCLOPRAMIDE HYDROCHLORIDE
1800	METOLAZONE
1801	METOPROLOL TARTRATE
1803	METRONIDAZOLE
1806	MEXILETINE HYDROCHLORIDE
1809	MICONAZOLE NITRATE
1818	MINOCYCLINE HYDROCHLORIDE
1819	MINOXIDIL
1820	MISOPROSTOL
1826	MOLINDONE HYDROCHLORIDE
1828	MOMETASONE FUROATE
1833	MORPHINE SULFATE
1843	MUPIROCIN
1849	NADOLOL
1856	NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE
1858	NANDROLONE DECANOATE
1860	NAPHAZOLINE HYDROCHLORIDE
1861	NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE
1864	NAPROXEN
1865	NAPROXEN SODIUM
1868	NEOMYCIN SULFATE
1869	NEOMYCIN SULFATE; POLYMYXIN B SULFATE
1870	NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE
1876	NIACIN
1882	NICARDIPINE HYDROCHLORIDE
1884	NICOTINE POLACRILEX
1886	NIFEDIPINE

1890	NITROFURANTOIN
1891	NITROFURANTOIN, MACROCRYSTALLINE
1893	NITROGLYCERIN
1894	NIZATIDINE
1900	NORETHINDRONE ACETATE
1901	NORFLOXACIN
1903	NORTRIPTYLINE HYDROCHLORIDE
1907	NYLIDRIN HYDROCHLORIDE
1908	NYSTATIN
1909	NYSTATIN; TRIAMCINOLONE ACETONIDE
1916	OMEPRAZOLE
1920	ORPHENADRINE CITRATE
1923	OXACILLIN SODIUM
1926	OXAZEPAM
1927	OXICONAZOLE NITRATE
1929	OXTRIPHYLLINE
1930	OXYBUTYNIN CHLORIDE
1932	OXYCODONE HYDROCHLORIDE
1948	PANCREATIN
1949	PANCRELIPASE
1953	PAPAVERINE HYDROCHLORIDE
1960	PAREGORIC
1963	PEMOLINE
1964	PENBUTOLOL SULFATE
1965	PENICILLAMINE
1968	PENICILLIN G POTASSIUM
1971	PENICILLIN V POTASSIUM
1972	PENTAERYTHRITOL TETRANITRATE
1977	PENTAZOCINE LACTATE

1980	PENTOXIFYLLINE
1986	PERGOLIDE MESYLATE
1988	PERPHENAZINE
1995	PHENAZOPYRIDINE HYDROCHLORIDE
1996	PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE
1998	PHENDIMETRAZINE TARTRATE
1999	PHENELZINE SULFATE
2002	PHENIRAMINE; PHENYLPROPANOLAMINE; PYRILAMINE
2003	PHENIRAMINE; PHENYLTOLOXAMINE; PYRILAMINE
2005	PHENOBARBITAL
2013	PHENOXYBENZAMINE HYDROCHLORIDE
2016	PENTERMINE HYDROCHLORIDE
2019	PHENYLBUTAZONE
2020	PHENYLEPHRINE HYDROCHLORIDE
2021	PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
2027	PHENYLPROPANOLAMINE HYDROCHLORIDE
2029	PHENYTOIN
2030	PHENYTOIN SODIUM
2035	PHYTONADIONE
2036	PILOCARPINE HYDROCHLORIDE
2038	PIMOZIDE
2039	PINDOLOL
2046	PIRBUTEROL ACETATE
2047	PIROXICAM
2069	POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE
2070	POLYTHIAZIDE; RESERPINE
2073	POTASSIUM
2078	POTASSIUM BICARBONATE

2081	POTASSIUM CHLORIDE
2084	POTASSIUM GLUCONATE
2085	POTASSIUM IODIDE
2086	POTASSIUM IODIDE; THEOPHYLLINE ANHYDROUS
2098	PRAZEPAM
2100	PRAZOSIN HYDROCHLORIDE
2102	PREDNISOLONE
2103	PREDNISOLONE ACETATE
2104	PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
2105	PREDNISOLONE SODIUM PHOSPHATE
2106	PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM
2109	PREDNISON
2114	PRIMIDONE
2115	PROBENECID
2116	PROBUCOL
2117	PROCAINAMIDE HYDROCHLORIDE
2118	PROCAINE HYDROCHLORIDE
2120	PROCHLORPERAZINE
2122	PROGESTERONE
2125	PROMETHAZINE HYDROCHLORIDE
2127	PROPAFENONE HYDROCHLORIDE
2128	PROPANTHELINE BROMIDE
2133	PROPOXYPHENE HYDROCHLORIDE
2134	PROPOXYPHENE NAPSYLATE
2135	PROPRANOLOL HYDROCHLORIDE
2138	PROPYLTHIOURACIL
2143	PROTRIPTYLINE HYDROCHLORIDE
2144	PSEUDOEPHEDRINE HYDROCHLORIDE



2145	PSEUDOEPHEDRINE HYDROCHLORIDE ; TRIPROLIDINE HYDROCHLORIDE
2150	PYRAZINAMIDE
2151	PYRIDOSTIGMINE BROMIDE
2152	PYRIDOXINE HYDROCHLORIDE
2156	PYRIMETHAMINE ; SULFADOXINE
2160	QUAZEPAM
2162	QUINESTROL
2165	QUINIDINE GLUCONATE
2166	QUINIDINE POLYGALACTURONATE
2167	QUINIDINE SULFATE
2168	QUININE SULFATE
2174	RANITIDINE HYDROCHLORIDE
2176	RAUWOLFIA SERPENTINA
2179	RESERPINE
2188	RIFAMPIN
2203	SALICYLIC ACID
2206	SALSALATE
2218	SELEGILINE HYDROCHLORIDE
2220	SELENIUM SULFIDE
2241	SODIUM BICARBONATE
2243	SODIUM CHLORIDE
2244	SODIUM FLUORIDE
2258	SODIUM POLYSTYRENE SULFONATE
2260	SODIUM SULFACETAMIDE ; SULFUR
2265	SOMATREM
2267	SORBITOL
2269	SPIRONOLACTONE
2270	STANNOUS FLUORIDE

2271	STANOZOLOL
2280	SUCRALFATE
2282	SULCONAZOLE NITRATE
2283	SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE
2284	SULFACETAMIDE SODIUM
2287	SULFAMETHIZOLE
2288	SULFAMETHOXAZOLE
2289	SULFAMETHOXAZOLE; TRIMETHOPRIM
2291	SULFAPYRIDINE
2292	SULFASALAZINE
2293	SULFINPYRAZONE
2294	SULFISOXAZOLE
2298	SULINDAC
2306	TAMOXIFEN CITRATE
2310	TEMAZEPAM
2311	TERAZOSIN HYDROCHLORIDE
2312	TERBUTALINE SULFATE
2313	TERCONAZOLE
2314	TERFENADINE
2318	TESTOSTERONE
2319	TESTOSTERONE CYPIONATE
2326	TETRACYCLINE HYDROCHLORIDE
2329	THEOPHYLLINE
2341	THIORIDAZINE HYDROCHLORIDE
2343	THIOTHIXENE
2348	THYROGLOBULIN
2349	THYROID
2353	TIMOLOL MALEATE

2355	TOBRAMYCIN
2357	TOCAINIDE HYDROCHLORIDE
2358	TOLAZAMIDE
2360	TOLBUTAMIDE
2361	TOLMETIN SODIUM
2366	TRANLYCYPROMINE SULFATE
2367	TRAZODONE HYDROCHLORIDE
2368	TRETINOIN
2370	TRIAMCINOLONE
2371	TRIAMCINOLONE ACETONIDE
2374	TRIAMTERENE
2375	TRIAZOLAM
2376	TRICHLORMETHIAZIDE
2381	TRIETHANOLAMINE POLYPEPTIDE OLEATE CONDENSATE
2382	TRIFLUOPERAZINE HYDROCHLORIDE
2385	TRIHEXYPHENIDYL HYDROCHLORIDE
2390	TRIMETHOBENZAMIDE HYDROCHLORIDE
2391	TRIMETHOPRIM
2394	TRIPLENNAMINE HYDROCHLORIDE
2396	TRIPROLIDINE HYDROCHLORIDE
2400	TROPICAMIDE
2418	URSODIOL
2419	VALPROIC ACID
2425	VERAPAMIL HYDROCHLORIDE
2444	WARFARIN SODIUM
2450	YOHIMBINE HYDROCHLORIDE
2451	ZIDOVUDINE
3004	CALCIUM ACETATE
3007	DOXAZOSIN MESYLATE

3009	ESTAZOLAM
3012	HALOBETASOL PROPIONATE
3014	ISRADIPINE
3015	LEVONORGESTREL
3016	OFLOXACIN
3017	OLSALAZINE SODIUM
3022	METIPRANOLOL HYDROCHLORIDE
3024	PEGADEMASE BOVINE
3029	ETODOLAC
3031	ONDANSETRON HYDROCHLORIDE
3032	RAMIPRIL
3037	HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
3046	FILGRASTIM
3052	FOSINOPRIL SODIUM
3053	BENAZEPRIL HYDROCHLORIDE
3059	FELODIPINE
3060	DIDANOSINE
3062	PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE
3063	TICLOPIDINE HYDROCHLORIDE
3064	PRAVASTATIN SODIUM
3066	AZITHROMYCIN DIHYDRATE
3068	CLARITHROMYCIN
3069	QUINAPRIL HYDROCHLORIDE
3072	AMLODIPINE BESYLATE
3076	ZALCITABINE
3078	FINASTERIDE
3084	NEDOCROMIL SODIUM
3087	SERTRALINE HYDROCHLORIDE

3088	SIMVASTATIN
3089	SOTALOL HYDROCHLORIDE
3090	SUMATRIPTAN SUCCINATE
3091	TACRINE HYDROCHLORIDE
3102	CEFPROZIL
3106	ISOSORBIDE MONONITRATE
3107	LORACARBEF
3108	NABUMETONE
3109	NICOTINE
3110	NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE
3126	CEFPODOXIME PROXETIL
3129	CLINDAMYCIN PHOSPHATE
3130	PAROXETINE HYDROCHLORIDE
3133	ITRACONAZOLE
3140	OXAPROZIN
3143	DESOGESTREL; ETHINYL ESTRADIOL
3145	ZOLPIDEM TARTRATE
3149	TERBINAFINE HYDROCHLORIDE
3156	SALMETEROL XINAFOATE
3161	LORATADINE
3164	CISAPRIDE MONOHYDRATE
3177	FLUOROMETHOLONE ACETATE
3179	TORSEMIDE
3182	RIMANTADINE HYDROCHLORIDE
7000	INSULIN
7500	KAOLIN; PAREGORIC; PECTIN
7501	HYDROCODONE BITARTRATE
7502	TIAPROFENIC ACID

7503	DIPHENOXYLATE HYDROCHLORIDE
0390	BELLADONNA; ERGOTAMINE; PHENOBARBITAL
1503	HYDROQUINONE
3184	LODOXAMIDE TROMETHAMINE

Appendix 2

CODE	DRUG CLASS DESCRIPTION
0100	ANESTHETICS
0117	ANESTHETICS, LOCAL
0118	ANESTHETICS, GENERAL
0119	ANESTHESIA, ADJUNCTS TO/ANALEPTICS
0120	MEDICINAL GASES
0121	ANESTHETICS, TOPICAL
0122	ANESTHETICS, OPHTHALMIC
0123	ANESTHETICS, RECTAL
0200	ANTIDOTES
0281	ANTIDOTES, SPECIFIC
0283	ANTIDOTES, GENERAL
0285	ANTITOXINS/ANTIVENINS
0286	ANAPHYLAXIS TREATMENT KIT
0300	ANTIMICROBIALS
0346	PENICILLINS
0347	CEPHALOSPORINS
0348	LINCOSAMIDES/MACROLIDES
0349	POLYMYXINS
0350	TETRACYCLINE
0351	CHLORAMPHENICOL/DERIVATIVES
0352	AMINOGLYCOSIDES
0353	SULFONAMIDES/RELATED COMPOUNDS
0354	ANTISEPTICS, URINARY TRACT
0355	ANTIBACTERIALS, MISCELLANEOUS
0356	ANTIMYCOBACTERIALS (INCL ANTI LEPROSY)
0357	QUINOLONES/DERIVATIVES
0358	ANTIFUNGALS
0388	ANTIVIRALS
0400	HEMATOLOGICS
0408	DEFICIENCY ANEMIAS
0409	ANTICOAGULANTS/THROMBOLYTICS
0410	BLOOD COMPONENTS/SUBSTITUTES
0411	HEMOSTATICS
0500	CARDIOVASCULAR-RENAL
0501	CARDIAC GLYCOSIDES
0502	ANTIARRHYTHMICS
0503	ANTIANGINALS
0504	VASCULAR DISORDERS, CEREBRAL/PERIPHERAL
0505	HYPOTENSION/SHOCK
0506	ANTIHYPERTENSIVES
0507	DIURETICS
0508	CORONARY VASODILATORS
0509	RELAXANTS/STIMULANTS, URINARY TRACT
0510	CALCIUM CHANNEL BLOCKERS
0511	CARBONIC ANHYDRASE INHIBITORS
0512	BETA BLOCKERS
0513	ALPHA AGONISTS/ALPHA BLOCKERS
0514	ACE INHIBITORS
0600	CENTRAL NERVOUS SYSTEM

Appendix 2 continued

CODE	DRUG CLASS DESCRIPTION
0626	SEDATIVES/HYPNOTICS
0627	ANTIANKXIETY
0628	ANTIPSYCHOTICS/ANTIMANICS
0630	ANTIDEPRESSANTS
0631	ANOREXIANTS/CNS STIMULANTS
0632	CNS, MISCELLANEOUS
0633	ALZHEIMER-TYPE DEMENTIA
0634	SLEEP AID PRODUCTS, PRIMARY OTC
0635	ANTIEMETICS
0700	CONTRAST MEDIA/ RADIOPHARMACEUTICALS
0789	DIAGNOSTICS, RADIOPAQUE & NONRADIOACTIVE
0790	DIAGNOSTICS RADIOPHARMACEUTICALS
0791	THERAPEUTICS RADIOPHARMACEUTICALS
0792	DIAGNOSTICS-MISC.
0800	GASTROINTESTINALS
0874	DISORDERS, ACID/PEPTIC
0875	ANTIDIARRHEALS
0876	LAXATIVES
0877	GASTROINTESTINAL, MISCELLANEOUS
0878	ANTISPASMODICS/ANTICHOLINERGICS
0879	ANTACIDS
0900	METABOLICS/NUTRIENTS
0912	HYPERLIPIDEMIA
0913	VITAMINS/MINERALS
0914	NUTRITION, ENTERAL/PARENTERAL
0915	REPL/REGS OF ELECTROLYTES/WATER BALANCE
0916	CALCIUM METABOLISM
0917	HEMATOPOIETICS
1000	HORMONES/HORMONAL MECHANISMS
1032	ADRENAL CORTICOSTEROIDS
1033	ADROGENS/ANABOLIC STEROIDS
1034	ESTROGENS/PROGESTINS
1035	ANTERIOR PITUITARY/HYPOTHALMIC FUNCTION
1036	BLOOD GLUCOSE REGULATORS
1037	THYROID/ANTITHYROID
1038	ANTIDIURETICS
1039	RELAXANTS/STIMULANTS, UTERINE
1040	CONTRACEPTIVES
1041	INFERTILITY
1042	DISORDERS OF GROWTH HORMONE SECRETION
1100	IMMUNOLOGICS
1180	VACCINES/ANTISERA
1181	IMMUNOMODULATORS
1182	ALLERGENIC EXTRACTS
1183	IMMUNE SERUMS (INCLUDES IMMUNE GLOBULINS)
1200	SKIN/MUCOUS MEMBRANES
1264	ANTISEPTICS/DISINFECTANTS
1265	DERMATOLOGICS
1266	KERATOLYTICS



Appendix 2 continued

CODE	DRUG CLASS DESCRIPTION
1267	ANTIPERSPIRANTS
1268	TOPICAL STEROIDS
1269	BURN/SUNBURN, SUNSCREEN
1270	ACNE PRODUCTS
1271	TOPICAL ANTI-INFECTIVES
1272	ANORECTAL PRODUCTS
1273	PERSONAL CARE PRODUCTS
1274	DERMATITIS/ANTIPURETICS
1275	TOPICAL ANALGESICS
1300	NEUROLOGICS
1371	EXTRAPYRAMIDAL MOVEMENT DISORDERS
1372	MYASTHENIA GRAVIS
1373	SKELETAL MUSCLE HYPERACTIVITY
1374	ANTICONVULSANTS
1400	ONCOLYTICS
1479	ANTINEOPLASTICS
1480	ANTINEOPLASTICS-HORMONAL/BIOLOGICAL RESPONSE
1481	ANTINEOPLASTICS-ANTIMETABOLITES
1482	ANTINEOPLASTIC AGENTS
1483	ANTINEOPLASTICS-DNA DAMAGING AGENTS
1500	OPHTHALMICS
1566	GLAUCOMA
1567	CYCOPLEGICS/MYDRIATICS
1568	OCULAR ANTI-INFECTIVE/ANTI-INFLAMMATORY
1569	OPHTHALMICS, MISCELLANEOUS
1570	OPHTHALMICS-DECONGESTANTS/ANTI-ALLERGY AGENTS
1571	CONTACT LENS PRODUCTS
1600	OTICS
1670	OTICS, TOPICAL
1671	VERTIGO/MOTION SICKNESS/VOMITING
1700	RELIEF OF PAIN
1720	ANALGESICS, GENERAL
1721	ANALGESICS, NARCOTIC
1722	ANALGESICS, NON-NARCOTIC
1723	ANTIMIGRAINE/OTHER HEADACHES
1724	ANTIARTHRITICS
1725	ANTIGOUT
1726	CENTRAL PAIN SYNDROMES
1727	NSAID-NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
1728	ANTIPYRETICS
1729	MENSTRUAL PRODUCTS
1800	ANTIPARASITICS
1860	ANTIPROTOZOALS
1862	ANTHELMINTICS
1863	SCABICIDES/PEDICULICIDES
1864	ANTIMALARIALS
1900	RESPIRATORY TRACT
1940	ANTIASTHMATICS/BRONCODILATORS
1941	NASAL DECONGESTANTS

Appendix 2 continued

CODE	DRUG CLASS DESCRIPTION
1943	ANTITUSSIVES/EXPECTORANTS/MUCOLYTICS
1944	ANTIHIAMINES
1945	COLD REMEDIES
1946	LOZENGE PRODUCTS
1947	CORTICOSTEROIDS-INHALATION/NASAL
2000	OTHER
2087	QUESTION OF USE
2095	PHARMACEUTICAL AIDS
2096	SURGICAL AIDS
2097	DENTAL PREPARATIONS
2098	DENTRIFICE/DENTURE PRODUCTS
2099	MOUTH PAIN, COLD SORE, CANKER SORE PRODUCTS
2100	HOMEOPATHIC PRODUCTS
9900	NO CLASS ASSIGNED
9998	MULTIPLE USES OF DRUG

Appendix 3

ICD-9-CM

Code      Description

```

=====
V01.1    Contact with or exposure to tuberculosis
V07.31   Prophylactic fluoride administration
V07.4    Postmenopausal hormone replacement therapy
V07.9    Unspecified prophylactic measure
V13.3    Personal history of diseases of skin and subcutaneous tissue
V15.0    Personal history of allergy, other than medicinal agents
V15.2    Personal history of surgery to other major organs
V15.82   Personal history of tobacco use
V22.2    Pregnant state, unspecified
V25.2    Encounter for sterilization
V25.9    Encounter for unspecified contraceptive management
V26.2    Procreative management, investigation and testing
V26.9    Unspecified procreative management
V40.3    Other behavioral problems
V40.9    Unspecified mental or behavioral problem
V41.6    Problems with swallowing and mastication
V42.0    Kidney transplant
V42.4    Bone transplant
V42.6    Lung transplant
V42.9    Unspecified organ or tissue transplant
V44.3    Colostomy
V45.6    Postsurgical states following surgery of eye and adnexa
V49.5    Other problems of limbs
V53.6    Fitting and adjustment of urinary devices
V58.1    Encounter or admission for chemotherapy
V58.9    Encounter for unspecified aftercare
V69.9    Problem related to lifestyle, unspecified
V74.1    Special screening examination for pulmonary tuberculosis
003.9    Salmonella infection, unspecified
005.9    Food poisoning, unspecified
008.8    Intestinal infections due to other organisms, not elsewhere
          classified
009.0    Infectious colitis, enteritis, and gastroenteritis
009.1    Colitis, enteritis, and gastroenteritis of presumed infectious
          origin
011.9    Pulmonary tuberculosis, unspecified
017.0    Tuberculosis of the skin and subcutaneous cellular tissue
033.9    Whooping cough, unspecified organism
034.0    Streptococcal sore throat
034.1    Scarlet fever
038.9    Unspecified septicemia
041.0    Streptococcus infection in conditions classified elsewhere and of
          unspecified site
041.1    Staphylococcus infection in conditions classified elsewhere and of
          unspecified site
041.9    Bacterial infection, unspecified
042      Human immunodeficiency virus [HIV] disease
049.9    Unspecified non-arthropod-borne viral diseases of central nervous
          system
052.9    Varicella without mention of complication
053.9    Herpes zoster without mention of complication

```

054.1 Genital herpes  
054.2 Herpetic gingivostomatitis  
054.9 Herpes simplex without mention of complication  
075 Infectious mononucleosis  
078.1 Viral warts  
079.9 Unspecified viral and chlamydial infections  
079.99 Unspecified viral infection  
084.6 Malaria, unspecified  
088.81 Lyme disease  
098.0 Acute gonococcal infections of the lower genitourinary tract  
099.9 Venereal disease, unspecified  
110.0 Dermatophytosis of scalp and beard  
110.1 Dermatophytosis of nail  
110.2 Dermatophytosis of hand  
110.3 Dermatophytosis of groin and perianal area  
110.4 Dermatophytosis of foot  
110.9 Dermatophytosis of unspecified site  
111.0 Pityriasis versicolor  
111.9 Dermatomycosis, unspecified  
112.0 Candidiasis of mouth  
112.1 Candidiasis of vulva and vagina  
112.9 Candidiasis of unspecified site  
117.9 Other and unspecified mycoses  
126.9 Ancylostomiasis and necatoriasis, unspecified  
127.4 Enterobiasis  
128.9 Helminth infection, unspecified  
133.0 Scabies  
135 Sarcoidosis  
136.9 Unspecified infectious and parasitic diseases  
149.0 Malignant neoplasm of pharynx, unspecified  
153.3 Malignant neoplasm of sigmoid colon  
173.4 Malignant neoplasm of scalp and skin of neck  
173.9 Malignant neoplasm of skin, site unspecified  
174.9 Malignant neoplasm of female breast, unspecified  
185 Malignant neoplasm of prostate  
189.0 Malignant neoplasm of kidney, except pelvis  
193 Malignant neoplasm of thyroid gland  
199.1 Other malignant neoplasm, unspecified site (primary) (secondary)  
208.9 Unspecified leukemia  
238.2 Neoplasm of uncertain behavior of skin  
239.6 Neoplasms of unspecified nature of brain  
239.9 Neoplasms of unspecified nature, site unspecified  
240.9 Goiter, unspecified  
242.0 Toxic diffuse goiter  
242.9 Thyrotoxicosis without mention of goiter or other cause  
244.9 Unspecified hypothyroidism  
246.9 Unspecified disorder of thyroid  
250.0 Diabetes mellitus without mention of complication  
250.9 Diabetes with unspecified complication  
251.9 Unspecified disorder of pancreatic internal secretion  
253.9 Unspecified disorders of pituitary gland  
255.4 Corticoadrenal insufficiency  
256.3 Other ovarian failure  
256.9 Unspecified ovarian dysfunction  
259.9 Unspecified endocrine disorder  
269.0 Vitamin K deficiency  
269.2 Unspecified vitamin deficiency

269.9 Unspecified nutritional deficiency  
272.0 Pure hypercholesterolemia  
272.5 Lipoprotein deficiencies  
272.9 Unspecified disorder of lipid metabolism  
274.0 Gouty arthropathy  
274.9 Gout, unspecified  
275.4 Disorders of calcium metabolism  
275.9 Unspecified disorder of mineral metabolism  
276.1 Hyposmolality and/or hyponatremia  
276.5 Volume depletion  
276.6 Fluid overload  
276.9 Electrolyte and fluid disorders not elsewhere classified  
277.0 Cystic fibrosis  
277.6 Other deficiencies of circulating enzymes  
278.8 Other hyperalimentation  
279.2 Combined immunity deficiency  
279.4 Autoimmune disease, not elsewhere classified  
279.9 Unspecified disorder of immune mechanism  
280.9 Iron deficiency anemia, unspecified  
282.6 Sickle-cell anemia  
285.9 Anemia, unspecified  
286.9 Other and unspecified coagulation defects  
287.5 Thrombocytopenia, unspecified  
289.9 Unspecified diseases of blood and blood-forming organs  
290.0 Senile dementia, uncomplicated  
295.3 Schizophrenia of the paranoid type  
295.9 Unspecified schizophrenia  
296.5 Bipolar affective disorder, depressed  
296.7 Bipolar affective disorder, unspecified  
296.8 Manic-depressive psychosis, other and unspecified  
297.9 Unspecified paranoid state  
298.9 Unspecified psychosis  
300.0 Anxiety states  
300.1 Hysteria  
300.21 Agoraphobia with panic attacks  
300.3 Obsessive-compulsive disorders  
300.9 Unspecified neurotic disorder  
302.71 Psychosexual dysfunction with inhibited sexual desire  
304.9 Unspecified drug dependence  
305.0 Alcohol abuse  
305.1 Tobacco use disorder  
305.9 Other, mixed, or unspecified drug abuse  
306.4 Gastrointestinal malfunction arising from mental factors  
307.23 Gilles de la Tourette's disorder  
307.42 Persistent disorder of initiating or maintaining sleep  
307.49 Other disorders of sleep of nonorganic origin  
307.5 Other and unspecified disorders of eating  
307.81 Tension headache  
308.0 Acute stress reaction, predominant disturbance of emotions  
308.2 Acute stress reaction, predominant psychomotor disturbance  
308.9 Unspecified acute stress  
311 Depressive disorder, not elsewhere classified  
312.89 Other specified conduct disorder, not elsewhere classified  
312.9 Unspecified disturbance of conduct  
314.0 Attention deficit disorder  
314.9 Unspecified hyperkinetic syndrome  
319 Unspecified mental retardation

322.9 Meningitis, unspecified  
331.0 Alzheimer's disease  
332.0 Paralysis agitans  
333.99 Other extrapyramidal diseases and abnormal movement disorders  
340 Multiple sclerosis  
344.9 Paralysis, unspecified  
345.9 Epilepsy, unspecified  
346.9 Migraine, unspecified  
347 Cataplexy and narcolepsy  
349.0 Reaction to spinal or lumbar puncture  
349.9 Unspecified disorders of nervous system  
350.1 Trigeminal neuralgia  
351.0 Bell's palsy  
351.9 Facial nerve disorder, unspecified  
354.0 Carpal tunnel syndrome  
355.9 Mononeuritis of unspecified site  
360.0 Purulent endophthalmitis  
360.9 Unspecified disorder of globe  
364.3 Unspecified iridocyclitis  
365.9 Unspecified glaucoma  
366.9 Unspecified cataract  
367.2 Astigmatism  
368.8 Other specified visual disturbances  
368.9 Unspecified visual disturbance  
369.8 Unqualified visual loss, one eye  
369.9 Unspecified visual loss  
371.9 Unspecified corneal disorder  
372.3 Other and unspecified conjunctivitis  
373.9 Unspecified inflammation of eyelid  
373.11 Hordeolum externum  
375.15 Tear film insufficiency, unspecified  
375.9 Unspecified disorder of lacrimal system  
379.9 Unspecified disorder of eye and adnexa  
379.91 Pain in or around eye  
379.93 Redness or discharge of eye  
380.12 Acute swimmers' ear  
380.4 Impacted cerumen  
380.9 Unspecified disorder of external ear  
382.9 Unspecified otitis media  
386.0 Meniere's disease  
386.12 Vestibular neuronitis  
386.3 Labyrinthitis  
386.9 Unspecified vertiginous syndromes and labyrinthine disorders  
388.3 Tinnitus  
388.7 Otalgia  
388.8 Other disorders of ear  
388.9 Unspecified disorder of ear  
391.9 Acute rheumatic heart disease, unspecified  
401.9 Unspecified essential hypertension  
410.9 Acute myocardial infarction, unspecified site  
413.9 Other and unspecified angina pectoris  
414.0 Coronary atherosclerosis  
416.0 Primary pulmonary hypertension  
423.9 Unspecified disease of pericardium  
424.0 Mitral valve disorders  
427.0 Paroxysmal supraventricular tachycardia  
427.1 Paroxysmal ventricular tachycardia

427.31 Atrial fibrillation  
427.41 Ventricular fibrillation  
427.69 Other premature beats  
427.9 Cardiac dysrhythmia, unspecified  
428.0 Congestive heart failure  
428.9 Heart failure, unspecified  
429.2 Cardiovascular disease, unspecified  
429.8 Other ill-defined heart diseases  
429.9 Heart disease, unspecified  
435.9 Unspecified transient cerebral ischemia  
436 Acute, but ill-defined, cerebrovascular disease  
437.7 Transient global amnesia  
437.9 Unspecified cerebrovascular disease or lesion  
440.2 Atherosclerosis of native arteries of the extremities  
440.9 Generalized and unspecified atherosclerosis  
443.9 Peripheral vascular disease, unspecified  
444.22 Arterial embolism and thrombosis of arteries of the lower extremities  
444.9 Arterial embolism and thrombosis of unspecified artery  
446.5 Giant cell arteritis  
447.9 Unspecified disorders of arteries and arterioles  
451.2 Phlebitis and thrombophlebitis of lower extremities, unspecified  
451.9 Phlebitis and thrombophlebitis of unspecified site  
453.9 Other venous embolism and thrombosis of unspecified site  
455.6 Unspecified hemorrhoids without mention of complication  
458.9 Hypotension, unspecified  
459.0 Hemorrhage, unspecified  
459.9 Unspecified circulatory system disorder  
460 Acute nasopharyngitis common cold  
462 Acute pharyngitis  
463 Acute tonsillitis  
464 Acute laryngitis and tracheitis  
464.4 Croup  
465.9 Acute upper respiratory infections of unspecified site  
471.9 Unspecified nasal polyp  
473.9 Unspecified sinusitis (chronic)  
474.12 Hypertrophy of adenoids alone  
474.9 Unspecified chronic disease of tonsils and adenoids  
477.0 Allergic rhinitis due to pollen  
477.8 Allergic rhinitis due to other allergen  
477.9 Allergic rhinitis cause unspecified  
478.1 Other diseases of nasal cavity and sinuses  
478.2 Other diseases of pharynx, not elsewhere classified  
478.7 Other diseases of larynx, not elsewhere classified  
478.9 Other and unspecified diseases of upper respiratory tract  
486 Pneumonia, organism unspecified  
487.1 Influenza with other respiratory manifestations  
487.8 Influenza with other manifestations  
490 Bronchitis, not specified as acute or chronic  
491.9 Unspecified chronic bronchitis  
492.8 Other emphysema  
493.9 Asthma, unspecified  
496 Chronic airway obstruction, not elsewhere classified  
501 Asbestosis  
511.9 Unspecified pleural effusion  
514 Pulmonary congestion and hypostasis  
515 Postinflammatory pulmonary fibrosis

518.89 Other diseases of lung, not elsewhere classified  
519.9 Unspecified disease of respiratory system  
520.7 Teething syndrome  
521.0 Dental caries  
521.9 Unspecified disease of hard tissues of teeth  
522.4 Acute apical periodontitis of pulpal origin  
522.5 Periapical abscess without sinus  
522.9 Other and unspecified diseases of pulp and periapical tissues  
523.1 Chronic gingivitis  
523.9 Unspecified gingival and periodontal disease  
524.6 Temporomandibular joint disorders  
525.1 Loss teeth due to accident/extraction/local periodontal disease  
525.9 Unspecified disorder of the teeth and supporting structures  
526.4 Inflammatory conditions of the jaws  
526.9 Unspecified disease of the jaws  
527.9 Unspecified disease of the salivary glands  
528.2 Oral aphthae  
528.3 Cellulitis and abscess of the oral soft tissues  
528.5 Diseases of lips  
528.9 Other and unspecified diseases of the oral soft tissues  
529.9 Unspecified condition of the tongue  
530.1 Esophagitis  
530.11 Reflux esophagitis  
530.2 Ulcer of esophagus  
530.81 Esophageal reflux  
530.9 Unspecified disorder of esophagus  
531.9 Gastric ulcer unspecified as acute or chronic, without mention of hemorrhage or perforation  
532.9 Duodenal ulcer unspecified as acute or chronic, without mention of hemorrhage or perforation  
533.9 Peptic ulcer, site unspecified, unspecified as acute or chronic, without mention of hemorrhage or perforation  
534.4 Gastrojejunal ulcer chronic or unspecified with hemorrhage  
534.9 Gastrojejunal ulcer unspecified as acute or chronic, without mention of hemorrhage or perforation  
535.5 Unspecified gastritis and gastroduodenitis  
536.8 Dyspepsia and other specified disorders of function of stomach  
536.9 Unspecified functional disorder of stomach  
537.9 Unspecified disorder of stomach and duodenum  
541 Appendicitis, unqualified  
553.3 Diaphragmatic hernia  
553.9 Hernia of unspecified site  
555.9 Regional enteritis unspecified site  
556.9 Ulcerative colitis, unspecified  
558.9 Other and unspecified noninfectious gastroenteritis and colitis  
562.0 Diverticula of small intestine  
562.00 Diverticulosis of small intestine (without mention of hemorrhage)  
562.01 Diverticulitis of small intestine (without mention of hemorrhage)  
564.0 Constipation  
564.1 Irritable colon  
564.6 Anal spasm  
564.9 Unspecified functional disorder of intestine  
569.3 Hemorrhage of rectum and anus  
569.9 Unspecified disorder of intestine  
573.3 Hepatitis, unspecified  
573.9 Unspecified disorder of liver  
574.2 Calculus of gallbladder without mention of cholecystitis



575.0 Acute cholecystitis  
575.9 Unspecified disorder of gallbladder  
577.9 Unspecified disease of pancreas  
586 Renal failure, unspecified  
590.9 Infection of kidney, unspecified  
592.0 Calculus of kidney  
593.9 Unspecified disorder of kidney and ureter  
595.9 Cystitis, unspecified  
596.8 Other specified disorders of bladder  
596.9 Unspecified disorder of bladder  
599.0 Urinary tract infection, site not specified  
599.7 Hematuria  
599.9 Unspecified disorder of urethra and urinary tract  
600 Hyperplasia of prostate  
601.9 Prostatitis, unspecified  
602.9 Unspecified disorder of prostate  
604.9 Other orchitis, epididymitis, and epididymo-orchitis, without mention of abscess  
607.84 Impotence of organic origin  
608.9 Unspecified disorder of male genital organs  
610.1 Diffuse cystic mastopathy  
610.4 Mammary duct ectasia  
611.0 Inflammatory disease of breast  
611.8 Other specified disorders of breast  
611.9 Unspecified breast disorder  
614.2 Salpingitis and oophoritis not specified as acute, subacute, or chronic  
614.9 Unspecified inflammatory disease of female pelvic organs and tissues  
615.9 Unspecified inflammatory disease of uterus  
616.0 Cervicitis and endocervicitis  
616.9 Unspecified inflammatory disease of cervix, vagina, and vulva  
617.9 Endometriosis, site unspecified  
620.2 Other and unspecified ovarian cyst  
620.8 Other noninflammatory disorders of ovary, fallopian tube, and broad ligament  
621.8 Other specified disorders of uterus, not elsewhere classified  
621.9 Unspecified disorder of uterus  
623.9 Unspecified noninflammatory disorder of vagina  
625.3 Dysmenorrhea  
625.4 Premenstrual tension syndromes  
625.9 Unspecified symptom associated with female genital organs  
626.2 Excessive or frequent menstruation  
626.4 Irregular menstrual cycle  
626.9 Unspecified disorders of menstruation and other abnormal bleeding from female genital tract  
627.2 Menopausal or female climacteric states  
627.9 Unspecified menopausal and postmenopausal disorder  
628.0 Female infertility associated with anovulation  
628.9 Female infertility of unspecified origin  
629.9 Unspecified disorder of female genital organs  
634.9 Spontaneous abortion without mention of complication  
644.0 Threatened premature labor  
666.34 Postpartum coagulation defects, postpartum condition or complication  
669.7 Cesarean delivery, without mention of indication  
676.6 Galactorrhea associated with childbirth and disorders of lactation

680.2 Carbuncle and furuncle of trunk  
680.9 Carbuncle and furuncle of unspecified site  
681.0 Cellulitis and abscess of finger  
681.02 Onychia and paronychia of finger  
681.1 Cellulitis and abscess of toe  
681.11 Onychia and paronychia of toe  
681.9 Cellulitis and abscess of unspecified digit  
682.2 Other cellulitis and abscess of trunk  
682.3 Other cellulitis and abscess of upper arm and forearm  
682.6 Other cellulitis and abscess of leg, except foot  
682.7 Other cellulitis and abscess of foot, except toes  
682.8 Other cellulitis and abscess of other specified sites  
682.9 Other cellulitis and abscess of unspecified site  
683 Acute lymphadenitis  
684 Impetigo  
686.9 Unspecified local infection of skin and subcutaneous tissue  
690 Erythematosquamous dermatosis  
691.0 Diaper or napkin rash  
691.8 Other atopic dermatitis and related conditions  
692.6 Contact dermatitis/eczema due to plants [except food]  
692.9 Contact dermatitis/eczema unspecified cause  
695.3 Rosacea  
696.1 Other psoriasis  
698.9 Unspecified pruritic disorder  
701.1 Keratoderma, acquired  
701.4 Keloid scar  
701.9 Unspecified hypertrophic and atrophic conditions of skin  
702.8 Other specified dermatoses  
703.0 Ingrowing nail  
704.0 Alopecia  
704.8 Other specified diseases of hair and hair follicles  
704.9 Unspecified disease of hair and hair follicles  
705.9 Unspecified disorder of sweat glands  
706.1 Other acne  
706.2 Sebaceous cyst  
707.1 Chronic ulcer of lower limbs, except decubitus  
707.9 Chronic ulcer of unspecified site  
708.9 Urticaria, unspecified  
709.9 Unspecified disorder of skin and subcutaneous tissue  
710.0 Systemic lupus erythematosus  
710.9 Unspecified diffuse connective tissue disease  
711.96 Unspecified infective arthritis of lower leg  
714.0 Rheumatoid arthritis  
715.00 Osteoarthritis, generalized, site unspecified  
716.66 Unspecified monoarthritis of lower leg  
716.9 Arthropathy, unspecified  
716.91 Arthropathy, unspecified, shoulder region  
716.92 Arthropathy, unspecified, upper arm  
716.94 Arthropathy, unspecified, hand  
716.95 Arthropathy, unspecified, pelvic region and thigh  
716.96 Arthropathy, unspecified, lower leg  
716.97 Arthropathy, unspecified, ankle and foot  
716.98 Arthropathy, unspecified, other specified sites  
719.0 Effusion of joint  
719.02 Effusion of joint, upper arm  
719.03 Effusion of joint, forearm  
719.06 Effusion of joint, lower leg

719.07 Effusion of joint, ankle and foot  
719.09 Effusion of joint, multiple sites  
719.4 Pain in joint  
719.41 Pain in joint, shoulder region  
719.42 Pain in joint, upper arm  
719.45 Pain in joint, pelvic region and thigh  
719.46 Pain in joint, lower leg  
719.47 Pain in joint, ankle and foot  
719.49 Pain in joint, multiple sites  
719.5 Stiffness of joint, not elsewhere classified  
719.56 Stiffness of lower leg joint, not elsewhere classified  
719.58 Stiffness of other specified joint sites, not elsewhere classified  
719.66 Other symptoms referable to lower leg joint  
719.81 Other specified disorders of joint, shoulder region  
719.9 Unspecified disorder of joint  
719.91 Unspecified disorder of joint, shoulder region  
719.93 Unspecified disorder of joint, forearm  
719.94 Unspecified disorder of joint, hand  
719.95 Unspecified disorder of joint, pelvic region and thigh  
719.96 Unspecified disorder of joint, lower leg  
719.97 Unspecified disorder of joint, ankle and foot  
720.0 Ankylosing spondylitis  
720.2 Sacroiliitis, not elsewhere classified  
720.9 Unspecified inflammatory spondylopathy  
722.1 Displacement of thoracic or lumbar intervertebral disc without myelopathy  
722.2 Displacement of intervertebral disc, site unspecified, without myelopathy  
722.6 Degeneration of intervertebral disc, site unspecified  
722.9 Other and unspecified disc disorder  
723.1 Cervicalgia  
723.9 Unspecified musculoskeletal disorders and symptoms referable to neck  
724.3 Sciatica  
724.5 Backache, unspecified  
724.9 Other unspecified back disorders  
725 Polymyalgia rheumatica  
726.1 Rotator cuff syndrome of shoulder and allied disorders  
726.11 Calcifying tendinitis of shoulder  
726.32 Lateral epicondylitis  
726.9 Unspecified enthesopathy  
726.91 Exostosis of unspecified site  
727.3 Other bursitis  
728.85 Spasm of muscle  
728.9 Unspecified disorder of muscle, ligament, and fascia  
729.0 Rheumatism, unspecified and fibrositis  
729.1 Myalgia and myositis, unspecified  
729.2 Neuralgia, neuritis, and radiculitis, unspecified  
729.5 Pain in limb  
729.81 Swelling of limb  
729.82 Cramp of limb  
729.9 Other and unspecified disorders of soft tissue  
730.2 Unspecified osteomyelitis  
730.96 Unspecified infection of lower leg bone  
731.0 Osteitis deformans without mention of bone tumor  
733.0 Osteoporosis  
733.9 Other and unspecified disorders of bone and cartilage

734 Flat foot  
735.4 Other hammer toe (acquired)  
775.2 Neonatal myasthenia gravis  
780.09 Other alteration of consciousness  
780.1 Hallucinations  
780.2 Syncope and collapse  
780.3 Convulsions  
780.4 Dizziness and giddiness  
780.5 Sleep disturbances  
780.52 Other insomnia  
780.57 Other and unspecified sleep apnea  
780.6 Fever  
780.7 Malaise and fatigue  
780.8 Hyperhidrosis  
780.9 Other general symptoms  
781.0 Abnormal involuntary movements  
782.0 Disturbance of skin sensation  
782.1 Rash and other nonspecific skin eruption  
782.2 Localized superficial swelling, mass, or lump  
782.3 Edema  
782.9 Other symptoms involving skin and integumentary tissues  
783.0 Anorexia  
783.2 Abnormal loss of weight  
783.6 Polyphagia  
784.0 Headache  
784.1 Throat pain  
784.2 Swelling, mass, or lump in head and neck  
784.7 Epistaxis  
784.9 Other symptoms involving head and neck  
785.0 Tachycardia, unspecified  
785.1 Palpitations  
785.2 Undiagnosed cardiac murmurs  
785.6 Enlargement of lymph nodes  
786.0 Dyspnea and respiratory abnormalities  
786.09 Other dyspnea and respiratory abnormalities  
786.2 Cough  
786.5 Chest pain  
786.6 Swelling, mass, or lump in chest  
786.7 Abnormal chest sounds  
786.8 Hiccough  
786.9 Other symptoms involving respiratory system and chest  
787.01 Nausea with vomiting  
787.02 Nausea alone  
787.03 Vomiting alone  
787.1 Heartburn  
787.2 Dysphagia  
787.3 Flatulence, eructation, and gas pain  
787.7 Abnormal feces  
787.9 Other symptoms involving digestive system  
788.0 Renal colic  
788.2 Retention of urine  
788.3 Incontinence of urine  
788.39 Other urinary incontinence  
788.41 Urinary frequency  
788.69 Other abnormality of urination  
788.9 Other symptoms involving urinary system  
789.0 Abdominal pain

790.6 Other abnormal blood chemistry  
790.9 Other nonspecific findings on examination of blood  
791.9 Other nonspecific findings on examination of urine  
795.5 Nonspecific reaction to tuberculin skin test without active tuberculosis  
799.2 Nervousness  
799.8 Other ill-defined conditions, causes of morbidity and mortality  
799.9 Other unknown and unspecified cause of morbidity and mortality  
803.0 Other and unqualified skull fractures closed without mention of intracranial injury  
805.8 Unspecified fracture of vertebral column without mention of spinal cord injury, closed  
807.0 Fracture of rib(s), closed  
814.0 Fracture of carpal bone(s), closed  
816.0 Fracture of one or more phalanges of hand, closed  
818.0 Ill-defined closed fractures of upper limb  
820.8 Fracture of unspecified part of neck of femur, closed  
826.0 Closed fracture of one or more phalanges of foot  
827.0 Closed other, multiple, and ill-defined fractures of lower limb  
839.8 Multiple and ill-defined dislocations, closed  
840.4 Sprains and strains of rotator cuff (capsule)  
840.9 Sprains and strains of unspecified site of shoulder and upper arm  
842.0 Sprains and strains of wrist  
844.9 Sprains and strains of unspecified site of knee and leg  
845.0 Sprains and strains of ankle  
845.1 Sprains and strains of foot  
847.0 Sprains and strains of neck  
847.2 Sprains and strains of lumbar back  
847.9 Sprains and strains of unspecified site of back  
848.3 Sprains and strains of ribs  
848.9 Unspecified site of sprain and strain  
873.4 Open wound of face, without mention of complication  
879.8 Open wound(s) (multiple) of unspecified site(s) without mention of complication  
879.9 Open wound(s) (multiple) of unspecified site(s), complicated  
892.0 Open wound of foot except toe(s) alone without mention of complication  
894.0 Multiple and unspecified open wound of lower limb without mention of complication  
910.2 Blister of face, neck, and scalp without mention of infection  
915.8 Other and unspecified superficial injury of fingers without mention of infection  
915.9 Other and unspecified superficial injury of fingers, infected  
916.2 Blister of hip, thigh, leg, and ankle w/o mention of infection  
917.8 Other and unspecified superficial injury of foot/toes w/o mention of infection  
918.1 Superficial injury of cornea  
918.9 Other and unspecified superficial injuries of eye  
919.4 Insect bite of other/multiple/unspecified site, nonvenomous, w/o mention of infection  
919.5 Insect bite of other/multiple/unspecified site, nonvenomous, infected  
919.8 Other and unspecified superficial injury without mention of infection  
923.0 Contusion of shoulder and upper arm  
923.9 Contusion of unspecified part of upper limb  
924.5 Contusion of unspecified part of lower limb

930.9 Foreign body on unspecified site of external eye  
933.1 Foreign body in larynx  
944.2 Burn of wrist(s) and hand(s) [second degree], blisters, epidermal  
loss  
957.9 Injury to nerves, unspecified site  
959.0 Face and neck injury, other and unspecified  
959.1 Trunk injury, other and unspecified  
959.3 Elbow, forearm, and wrist injury, other and unspecified  
959.4 Hand injury, other and unspecified, except finger  
959.5 Finger injury, other and unspecified  
959.6 Hip and thigh injury, other and unspecified  
959.7 Knee, leg, ankle, and foot injury, other and unspecified  
959.8 Injury to other specified sites, including multiple  
959.9 Injury to unspecified site  
984.9 Toxic effect of unspecified lead compound  
989.5 Toxic effect of venom  
994.6 Motion sickness  
995.2 Unspecified adverse effect of drug, medicinal and biological  
substance (due) to correct medicinal substance properly  
administered  
995.3 Allergy, unspecified  
995.69 Anaphylactic shock due to other specified food  
996.8 Complications of transplanted organ  
997.6 Late amputation stump complication, not elsewhere classified  
999.3 Other infection following medical care, not elsewhere classified  
888888 Blank but applicable  
999999 Sample person did not know symptom or condition

References:

Denniston PL Jr, Epner JA, eds. Physicians GenRx, 1994: The Official Drug Reference. Smithtown, NY: Data Pharmaceutica Inc. 1993.

Product Information Management Branch. National Drug Code Directory. Vol. II. Rockville, MD: Food and Drug Administration. 1985.